Document:

Form of Exchange and Purchase Agreement

 Exhibit 10.1 
 EXCHANGE AND PURCHASE AGREEMENT 

                      
       (including any other persons or entities exchanging Existing Notes (as defined below) or purchasing New Notes (as defined below) hereunder for whom the undersigned Holder holds contractual and investment
authority, the “Holder”) enters into this Exchange and Purchase Agreement (the “Agreement”) with Savient Pharmaceuticals, Inc., a Delaware corporation (the “Company”), on May 7, 2012 whereby
the Holder will (a) exchange (the “Exchange”) certain of the Company’s 4.75% Convertible Senior Notes due 2018 (the “Existing Notes”) for certain of the Company’s Units (as defined below),
each Unit consisting of (i) $1,000 principal amount at maturity new Senior Secured Discount Notes due 2019 (the “New Notes”) that will be issued pursuant to the provisions of an Indenture, to be dated as of May 9,
2012 in the form of Exhibit A hereto (the “Indenture”) between the Company, each of the guarantors named therein (the “Guarantors”) and U.S. Bank National Association, as Trustee (the
“Trustee”) and collateral agent (the “Collateral Agent”) and (ii) 23.4 warrants (each such warrant, a “Warrant”) to purchase common stock (the “Warrant Shares”) on the terms
set forth in the Warrant Agreement, to be dated as of May 9, 2012 (the “Warrant Agreement”) between the Company and U.S. Bank National Association, as warrant agent (clauses (i) and (ii) above together constitute a
“Unit” (and, together with the New Notes and Warrants which the Units represent, the “Securities”), issued pursuant to one or more unit certificates, collectively, the “Unit Certificates”) and/or
(b) purchase for cash (the “Purchase,” if applicable, and together with the Exchange, is referred to herein as the “Exchange and Purchase”) additional New Notes and Warrants, to be issued in the form of Units.
The New Notes and the guarantees of the New Notes (the “Guarantees”) will have the benefit of the Collateral Documents (as defined in the Indenture), pursuant to which the Company and each Guarantor will, among other things, grant
first priority security interests in and liens on certain of the assets and properties of the Company and the Guarantors, as described in the Indenture and the Collateral Documents (the “Collateral”). This Agreement, the Indenture,
the New Notes, the Guarantees, the Collateral Documents, the Warrant Agreement, the Warrants, the Units and the Unit Certificates and the Other Agreements (defined below) are collectively herein referred to as the “Transaction
Documents.” 
 On and subject to the terms hereof, the parties hereto agree as follows: 

Article I: Exchange of Existing Notes and Purchase of New Notes 

Section 1.1 Exchange. At the Closing (as defined herein), the Holder hereby agrees to exchange and deliver to the
Company the following Existing Notes, and in exchange therefor the Company hereby agrees to issue to the Holder the principal amount of New Notes, in the form of Units (which shall include 23.4 Warrants for each $1,000 principal amount at maturity
of New Notes), described below and to pay in cash the following accrued but unpaid interest, through the Closing, on such Existing Notes: 
  

			
	 Principal Amount of Existing Notes to be Exchanged:
	  	$                            
                             
		  	(the “Exchanged Existing Notes”).
	 Principal Amount of New Notes to be Issued in the Exchange:
	  	$                            
                             
		  	 (the “Exchanged New Notes”).

	 Cash Payment of Accrued but Unpaid Interest on Exchanged Existing Notes:
	  	$                            
                             
		  	 (the “Cash Payment”).

 Section 1.2 Purchase. At the Closing (as defined herein), the Holder hereby agrees
to purchase from the Company, and the Company hereby agrees to issue and sell to the Holder, the following principal amount of the New Notes, in the form of Units (which shall include 23.4 Warrants for each $1,000 principal amount at maturity of New
Notes), for the cash purchase price specified below: 
  

			
	 Principal Amount of Notes to be Purchased:
	  	$                            
                             
		  	 (the “Purchased New Notes”)

	 Purchase Price for Purchased New Notes:
	  	73.784032% of the principal amount of the Purchased New Notes ($____________) (the “Purchase Price”).

  
 Page 1 of 13

 Section 1.3 Closing. Subject to the terms and conditions hereof, the
closing (the “Closing”) of the Exchange and Purchase shall occur on May 9, 2012 (the “Closing Date”) or such other date as the parties hereto may agree in writing. At the Closing, (a) the Holder shall
deliver or cause to be delivered to the Company (i) all right, title and interest in and to the Exchanged Existing Notes free and clear of any mortgage, lien, pledge, charge, security interest, encumbrance, title retention agreement, option,
equity or other adverse claim thereto (collectively, “Liens”), together with any documents of conveyance or transfer that the Company may deem necessary or desirable to transfer to and confirm in the Company all right, title and
interest in and to the Exchanged Existing Notes free and clear of any Liens and (ii) the Purchase Price, in immediately available cash in U.S. dollars, (b) the Company shall issue to the Holder the Exchanged New Notes and the Purchased New
Notes (collectively, the “Holder’s New Notes”) in the form of Units and shall deliver to the Holder the Cash Payment and (c) the Company shall issue to the Holder the Warrants in the form of Units pursuant to the Warrant
Agreement; provided, however, that the parties acknowledge that the issuance of the Units to the Holder may be delayed due to procedures and mechanics within the system of the Depository Trust Company and that such delay will not be a default under
this Agreement so long as (i) the Company is using reasonable best efforts to effect the issuance of one or more global notes representing the Units, (ii) such delay is no longer than three business days, and (iii) interest shall
accrue on such New Notes from the date of the Indenture. Simultaneously with or after the Closing, the Company may issue Units to one or more other holders of outstanding Existing Notes or to other investors, subject to the terms of the Indenture
and the Warrant Agreement, respectively. Upon delivery of the Existing Notes to the Company, the Existing Notes and all obligations thereunder and pursuant thereto shall be cancelled and extinguished. 

Section 1.4 Conditions to Closing.  

(a) The obligation of the Holder hereunder to consummate the Exchange and Purchase contemplated hereby at the Closing is
subject to the satisfaction, at or before the Closing Date, of each of the following conditions, provided that these conditions are for the Holder’s sole benefit and may be waived by the Holder at any time in its sole discretion by providing
the Company with prior written notice thereof: 
 (i) The Company and the Guarantors shall have executed and
delivered each of the Transaction Documents, other than any Other Agreements, to which they are a party; 
 (ii)
The Company and the Guarantors shall have performed in all material respects all of their covenants and obligations to be performed prior to the Closing Date under the Transaction Documents, other than any Other Agreements; 

(iii) The Company and the Guarantors shall have delivered to the Holder a certificate of the Company and each Guarantor,
dated the Closing Date, executed by the secretary of the Company and each Guarantor certifying in such capacity and on behalf of the Company (i) as to the incumbency and signature of the officer of the Company and each Guarantor who executed
any of the Transaction Documents; and (ii) as to the adoption of resolutions of the board of directors of the Company and each Guarantor which are in full force and effect on the Closing Date, authorizing (x) the execution and delivery of
the Transaction Documents, other than any Other Agreements, and (y) the performance of the obligations of the Company and each Guarantor thereunder; 
 (iv) The Company shall have delivered to the Holder a certificate of the Chief Executive Officer or Chief Financial Officer of the Company, dated the Closing Date, to the effect that the representations
and warranties of the Company in this Agreement are true and correct in all material respects (except for those representations and warranties that are qualified by materiality, which shall be true and correct in all respects) as of the date when
made and as of the Closing Date with the same effect as if made on the Closing Date (except for representations and warranties that speak as of a specific date, which shall be true and correct as of such specified date) and that the Company and the
Guarantors have complied in all material respects with all the agreements and satisfied all the conditions on its part to be performed or satisfied at or prior to the Closing Date; 

(v) Simultaneously with the Closing, the Company shall issue an aggregate principal amount of New Notes that, together
with notes issued to Other Holders (as defined below) is not less than $170,941,000, of which at least $107,559,000 aggregate principal amount shall be Exchanged New Notes; 

  
 Page 2 of 13

 (vi) The Company shall have obtained Committee on Uniform Securities
Identification Procedures numbers (CUSIP numbers) for each of the Securities. On the Closing Date, the Units shall be eligible for deposit at DTC and for DTC book-entry services; 

(vii) Upon the execution and delivery of the Collateral Documents and, following the Closing, the filing of financing
statements (containing adequate descriptions of the personal property Collateral pursuant to the Uniform Commercial Code) with the appropriate governmental authorities (including payment of the appropriate filing or recording fees and any applicable
taxes) and delivery of the applicable documents to the Collateral Agent in accordance with the provisions of the Collateral Documents, the Collateral Agent, for and on behalf of itself, the Trustee and each Holder, will have a valid and perfected
first priority lien on the Collateral, subject to Liens permitted to be incurred under the Indenture and Collateral Documents; 
 (viii) The Units, as of the Closing Date, satisfy the requirements set forth in Rule 144A(d)(3) under the Securities Act; and 

(ix) The Company shall have delivered to Holder the opinion of Wilmer Cutler Pickering Hale and Dorr LLP, dated as of the
Closing Date, in substantially the form of Exhibit B attached hereto. 
 (b) The obligation of the Company
hereunder to consummate the transactions contemplated hereby at the Closing is subject to the satisfaction, at or before the Closing Date, of each of the following conditions, provided that these conditions are for the Company’s sole benefit
and may be waived by the Company at any time in its sole discretion by providing the Holder with prior written notice thereof: 
 (i) The Holder shall have executed and delivered to the Company each of the Transaction Documents to which it is a party; 

(ii) The Holder shall have delivered, or caused to be delivered, to the Company the Existing Notes being exchanged
pursuant to this Agreement and the Purchase Price in accordance with the written instructions of the Company; 

(iii) The representations and warranties of the Holder in this Agreement shall be true and correct in all material
respects (except for those representations and warranties that are qualified by materiality, which shall be true and correct in all respects) as of the date when made and as of the Closing Date with the same effect as if made on the Closing Date
(except for representations and warranties that speak as of a specific date, which shall be true and correct as of such specified date); and 
 (iv) There shall not be in effect any laws, regulations or governmental or judicial decrees, injunctions or orders restraining, enjoining or otherwise prohibiting the consummation of the Exchange and
Purchase contemplated hereby. 
 Section 1.5 Exchange and Sale of Additional New Notes. Simultaneously with
the Closing, the Company (i) may enter into one or more agreements (the “Other Agreements”) with one or more holders (the “Other Holders”) of Existing Notes to exchange New Notes with one or more Other Holders
for Existing Notes, subject to the terms of the Indenture, in an aggregate principal amount that, together with the New Notes issued pursuant to this Agreement, is not less than $170,941,000, and (ii) may issue additional New Notes pursuant to
one or more Other Agreements, subject to the terms of the Indenture, with one or more Other Holders and/or any new Holders, so long as the purchase price for any such additional New Notes is not less than $737.84032 per $1,000 principal amount of
New Notes. 
 Article II: Covenants, Representations and Warranties of the Holder 

The Holder hereby covenants as follows, and makes the following representations and warranties, each of which is and shall be true and
correct on the date hereof and on the Closing Date, to the Company and Cowen and Company, LLC, and all such covenants, representations and warranties shall survive the Closing. 

  
 Page 3 of 13

 Section 2.1 Power and Authorization. The Holder is duly organized,
validly existing and in good standing, and has the power, authority and capacity to execute and deliver this Agreement and each other Transaction Document to which it is a party, to perform its obligations hereunder and thereunder, and to consummate
the Exchange and Purchase contemplated hereby and thereby. If the Holder that is signatory hereto is executing this Agreement or the other Transaction Documents to which it is a party to effect the exchange of Exchanged Existing Notes beneficially
owned by one or more other persons or entities or to effect the purchase of the Purchased New Notes by one or more other persons or entities (all of whom are thus included in the definition of “Holder” hereunder), (a) such signatory
Holder has all requisite discretionary authority to enter into this Agreement and such other Transaction Documents on behalf of, and bind, each such other person or entity that is a beneficial owner of Exchanged Existing Notes or that is purchasing
Purchased New Notes; (b) Exhibit C hereto is a true, correct and complete list of (i) the name of each party delivering (as beneficial owner) Exchanged Existing Notes hereunder, (ii) the principal amount of such
Holder’s Exchanged Existing Notes, (iii) the principal amount of Exchanged New Notes to be issued to such Holder in respect of its Exchanged Existing Notes, (iv) the amount of the cash payment to be made to such Holder in respect of
the accrued interest on its Exchanged Existing Notes and (v) the DTC Participant or broker name of, DTC Participant or broker contact name for, and DTC Participation number of such Holder or its applicable broker; and
(c) Exhibit D hereto is a true, correct and complete list of (i) the name of each party acquiring (as beneficial owner) Purchased New Notes hereunder, (ii) the principal amount of Purchased New Notes being acquired by such
Holder and (iii) the DTC Participant name of, DTC Participant contact name for, and DTC Participation number of such Holder. 
 Section 2.2 Valid and Enforceable Agreement: No Violations. This Agreement and each other Transaction Document to which it is a party has been (or by the Closing will have been) duly
executed and delivered by the Holder and constitutes or will constitute a legal, valid and binding obligation of the Holder, enforceable against the Holder in accordance with their respective terms, except that such enforcement may be subject to
(a) bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium or other similar laws affecting or relating to enforcement of creditors’ rights generally, and (b) general principles of equity, whether such enforceability
is considered in a proceeding at law or in equity (the “Enforceability Exceptions”). This Agreement, each other Transaction Document to which the Holder is a party, and consummation of the Exchange and Purchase contemplated herein
and therein will not violate, conflict with or result in a breach of or default under (i) the Holder’s organizational documents, (ii) any agreement or instrument to which the Holder is a party or by which the Holder or any of its
assets are bound, or (iii) any laws, regulations or governmental or judicial decrees, injunctions or orders applicable to the Holder, except, in the case of clauses (ii) and (iii), as would not, individually or in the aggregate, be
reasonably expected to have a material adverse effect on the ability of the Holder to perform its obligations under this Agreement or the other Transaction Documents to which it is a party. 

Section 2.3 Title to the Exchanged Existing Notes. The Holder is the sole legal and beneficial owner of the
Exchanged Existing Notes and all rights and interests therein and thereto, and the Holder has good, valid and marketable title to the Exchanged Existing Notes, free and clear of any Liens (other than pledges or security interests that the Holder may
have created in favor of a prime broker under and in accordance with its prime brokerage agreement with such broker). The Holder has not, in whole or in part, except as described in the preceding sentence, (a) assigned, transferred,
hypothecated, pledged, exchanged or otherwise disposed of any of the Exchanged Existing Notes or its rights in the Exchanged Existing Notes, or (b) given any person or entity any transfer order, power of attorney or other authority of any
nature whatsoever with respect to the Exchanged Existing Notes. Upon the Holder’s delivery of the Exchanged Existing Notes to the Company pursuant to the Exchange, the Exchanged Existing Notes shall be free and clear of all Liens. 

Section 2.4 Qualified Institutional Buyer. The Holder is a “qualified institutional buyer” within the
meaning of Rule 144A promulgated under the Securities Act of 1933, as amended (the “Securities Act”) and was not organized for the purpose of acquiring the New Notes or the Warrants. 

Section 2.5 No Affiliate Status. The Holder is not, and has not been during the consecutive three month period
preceding the date hereof, a director, officer or “affiliate” within the meaning of Rule 144 promulgated under the Securities Act (an “Affiliate”) of the Company. 

Section 2.6 Restricted Securities. The Holder (a) acknowledges that the issuance of all the Holder’s
Securities pursuant to the Exchange and Purchase has not been and will not be registered under the Securities Act or any state securities laws, and the Holder’s Securities are being offered and sold in reliance upon exemptions provided in the
Securities Act and state securities laws for transactions not involving any public offering which depend upon, among other things, the accuracy of certain of the Holder’s representations as expressed herein, (b) understands that

  
 Page 4 of 13

 
the Securities are “restricted securities” under applicable securities laws and that, pursuant to these laws and, therefore, cannot be sold, transferred, offered for sale, pledged,
hypothecated or otherwise disposed of unless they are subsequently registered and qualified under the Securities Act and applicable state laws or unless an exemption from such registration and qualification is available, and that evidence of the
Holder’s Securities will bear one or more legends to such effect and as otherwise required by the Indenture or the Warrant Agreement, as applicable (with the removal of any such legend governed by the terms of the Indenture or Warrant
Agreement, respectively), and (c) is acquiring the Holder’s Securities for investment purposes only, for the account of the Holder and not with any view toward a distribution thereof or with any intention of selling, distributing or
otherwise disposing of the Holder’s Securities in a manner that would violate the registration requirements of the Securities Act. The Holder is able to bear the economic risk of holding the Holder’s Securities for an indefinite period and
has sufficient knowledge and experience in financial and business matters so as to be capable of evaluating the merits and risks of its investment in the Holder’s Securities. The Indenture is not qualified under the Trust Indenture Act of 1939,
as amended (the “TIA”), and the Holder will not, as of the Closing Date, have the protection of any provision of the TIA. 
 Section 2.7 No Illegal Transactions. The Holder has not, directly or indirectly, and no person acting on behalf of or pursuant to any understanding with the Holder has, engaged in any
transactions in the securities of the Company (including, without limitation, any Short Sales (as defined below) involving any of the Company’s securities) since the time that such Holder was first contacted by either the Company, Cowen and
Company, LLC or any other person regarding an investment in the New Notes or the Company. Such Holder covenants that neither it nor any person acting on its behalf or pursuant to any understanding with such Holder will engage, directly or
indirectly, in any transactions in the securities of the Company (including Short Sales) prior to the time the transactions contemplated by this Agreement are publicly disclosed. “Short Sales” means “short sales” as
defined in Rule 200 of Regulation SHO promulgated under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and all types of direct and indirect stock pledges, forward sale contracts, options, puts,
calls, short sales, swaps, derivatives and similar arrangements (including on a total return basis), and sales and other transactions through non-U.S. broker-dealers or foreign regulated brokers. Solely for purposes of this Section 2.7,
subject to the Holder’s compliance with its obligations under the U.S. federal securities laws and the Holder’s internal policies, “Holder” shall not be deemed to include any subsidiaries or affiliates of the Holder that are
effectively walled off by appropriate “Chinese Wall” information barriers approved by the Holder’s legal or compliance department (and thus have no knowledge of and have not been privy to any information concerning the Exchange and
Purchase). 
 Section 2.8 Adequate Information: No Reliance. The Holder acknowledges and agrees that
(a) the Holder has been furnished with all materials relating to the Company and the Exchange and Purchase that the Holder considers necessary or appropriate to making an investment decision to enter into the Exchange and Purchase and to invest
in the Holder’s Securities and has had the opportunity to review the Company’s filings with the Securities and Exchange Commission (the “SEC”), including, without limitation, all filings made pursuant to the Exchange Act
(collectively, the “SEC Documents”), (b) the Holder has had a full opportunity to ask questions of the Company and its representatives concerning the Company, its business, operations, financial performance, financial condition
and prospects, and the terms and conditions of the Exchange and Purchase, (c) the Holder understands that its investment in the Securities involves a high degree of risk and has had the opportunity to consult with its accounting, tax, financial
and legal advisors to be able to evaluate the risks involved in the Exchange and Purchase and to make an informed investment decision with respect to the Exchange and Purchase and (d) the Holder has had such opportunity to obtain from
representatives of the Company such materials relating to the Company and the Exchange and Purchase as is necessary to permit it to evaluate the merits and risks of its investment in the Company and has independently, without reliance upon any
representatives of the Company and based on such materials relating to the Company and the Exchange and Purchase as the Holder deemed necessary and appropriate, made its own analysis and decision to enter into this Agreement and the other
Transaction Documents to which it is a party. 
 Section 2.9 No Public Market. The Holder understands that
no public market exists for the New Notes or Warrants, and that there is no assurance that a public market will ever develop for the New Notes or Warrants. 
 Article III: Covenants, Representations and Warranties of the Company 
 The Company hereby covenants as follows, and makes the following representations and warranties, each of which is and shall be true and correct on the date hereof and on the Closing Date, to the Holder,
and all such covenants, representations and warranties shall survive the Closing. 

  
 Page 5 of 13

 Section 3.1 Power and Authorization. The Company and each Guarantor is
duly incorporated, validly existing and in good standing under the laws of its jurisdiction of incorporation, and has the power, authority and capacity to execute and deliver this Agreement and each other Transaction Document (other than any Other
Agreements) to which it is a party, to perform its obligations hereunder and thereunder, and to consummate the Exchange and Purchase contemplated hereby and thereby. 
 Section 3.2 Valid and Enforceable Agreements; No Violations. This Agreement and each other Transaction Document (other than any Other Agreements) to which the Company is a party has
been (or by the Closing will have been) duly executed and delivered by the Company and constitutes (or will constitute) a legal, valid and binding obligation of the Company, enforceable against the Company in accordance with their respective terms,
except that such enforcement may be subject to the Enforceability Exceptions. Each Transaction Document to which the Guarantors are a party (other than any Other Agreements) has been (or by the Closing will have been) duly executed and delivered by
each Guarantor and constitutes (or will constitute) a legal, valid and binding obligation of each Guarantor, enforceable against each Guarantor in accordance with its terms, except that such enforcement may be subject to the Enforceability
Exceptions. At the Closing, the Indenture will govern the terms of the Holder’s New Notes and the Warrant Agreement will govern the terms of the Holder’s Warrant. All consents, approvals, orders and authorizations required on the part of
the Company and the Guarantors in connection with the execution, delivery or performance of the Transaction Documents and the consummation of the Exchange and Purchase have been obtained and will be effective as of the Closing Date, other than
(i) such filings required to be made after the Closing under applicable federal and state securities laws, (ii) filings required for the perfection of the security interests under the Collateral Documents and (iii) with respect to any
of the foregoing, where the failure to make or obtain would not reasonably be expected to have a material adverse effect on, or a material adverse change in, (A) the business, operations, financial condition, prospects or results of operations
of the Company and its subsidiaries, taken as a whole, or (B) the ability of the Company or the Guarantors to perform their obligations under this Agreement and the other Transaction Documents (other than any Other Agreements), as applicable (a
“Material Adverse Effect”). The entering into of the Transaction Documents (other than any Other Agreements) and the consummation of the Exchange and Purchase will not violate, conflict with or result in a breach of or default under
(i) the charter, bylaws or other organizational documents of the Company or the Guarantors, (ii) any agreement or instrument to which the Company or any Guarantors is a party or by which the Company or any Guarantors or any of their assets
are bound, or (iii) any laws, regulations or governmental or judicial decrees, injunctions or orders applicable to the Company or any Guarantors, except, in the case of clauses (ii) and (iii), as would not, individually or in the
aggregate, be reasonably expected to have a Material Adverse Effect. 
 Section 3.3 Validity of the Holder’s
Securities. The Holder’s Securities have been duly authorized by the Company and, when executed and authenticated in accordance with the provisions of the Indenture, with respect to the New Notes, or the Warrant Agreement, with respect
to the Warrant, and delivered to the Holder pursuant to the Exchange and Purchase against delivery of the Exchanged Existing Notes and payment of the Purchase Price in accordance with the terms of this Agreement, the Holder’s Securities will be
valid and binding obligations of the Company, enforceable in accordance with their respective terms, except in each case that such enforcement may be subject to the Enforceability Exceptions. The issuance of the Holder’s Securities will not be
subject to any preemptive, participation, rights of first refusal and other similar rights. Assuming the accuracy of the Holder’s representations and warranties hereunder, the Holder’s Securities (i) will be issued in the Exchange and
Purchase exempt from the registration requirements of the Securities Act pursuant to Section 4(2) of the Securities Act and Rule 506 of Regulation D promulgated under the Securities Act, and (ii) will be issued in compliance with
all applicable state and federal laws concerning the issuance of the Holder’s Securities. 
 Section 3.4 Legal
Proceedings. No legal or governmental proceedings or investigations are pending or, to the knowledge of the Company, threatened to which the Company or any of its subsidiaries is a party or to which the property of the Company or any of its
subsidiaries is subject that are not described in the SEC Documents, except for such proceedings or investigations which would not reasonably be expected to, singly or in the aggregate, result in a Material Adverse Effect. 

Section 3.5 Compliance with Laws. The Company and its subsidiaries possess all certificates, authorizations and
permits issued by the appropriate federal, state or foreign regulatory authorities necessary to conduct their respective businesses, except where the failure to have such certificates, authorizations and permits would not reasonably be expected to
have a Material Adverse Effect, and none of the Company and its subsidiaries has received any notice of proceedings relating to the revocation or modification of any such certificate, authorization

  
 Page 6 of 13

 
or permit which would reasonably be expected to, singly or in the aggregate, result in a Material Adverse Effect. The Company and its subsidiaries are and have been in compliance with all
applicable laws, statutes, ordinances, rules, regulations, orders, judgments, decisions, decrees, standards, and requirements relating to their respective businesses, except where any such non-compliance would not reasonably be expected to have a
Material Adverse Effect. 
 Section 3.6 No Material Adverse Effect. Since the respective dates as of which
information is given in the SEC Documents, (a) there has not been any material change in the business, operations, prospects, properties or condition (financial or otherwise) or results of operations of the Company and its subsidiaries, taken
as a whole, whether or not arising in the ordinary course of business; and (b) neither the Company nor any of its subsidiaries has sustained any material loss or interference with its business from fire, explosion, flood or other calamity,
whether or not covered by insurance, or from any labor dispute or court or governmental action, order or decree, in each case, that has had, or could reasonably be expected to have, a Material Adverse Effect. 

Section 3.7 Disclosure. On or before the first business day following the date of this Agreement, the Company shall
issue a press release or file with the SEC a Current Report on Form 8-K disclosing all material terms of the Exchange and Purchase and any other nonpublic information that is material to the Company and was delivered by the Company or its
agents or counsel to the Holder or any agent acting on its behalf (to the extent not previously publicly disclosed). 

Article IV: Miscellaneous 
 Section 4.1 Reasonable Best Efforts. Each party shall use its reasonable best efforts to satisfy each of the conditions to be satisfied by it as provided in Section 1.4 of this
Agreement. 
 Section 4.2 Further Assurances. The Holder and the Company each hereby agree to execute and
deliver, or cause to be executed and delivered, such other documents, instruments and agreements, and take such other actions, as either party may reasonably request in connection with the transactions contemplated by this Agreement. 

Section 4.3 Costs and Expenses. The Holder and the Company shall each pay their own respective costs and expenses
incurred in connection with the negotiation, preparation, execution and performance of this Agreement, including, but not limited to, attorneys’ fees. 
 Section 4.4 Notice. Any notice provided for in this Agreement shall be in writing and shall be either personally delivered, or mailed first class mail (postage prepaid) with return
receipt requested or sent by reputable overnight courier service (charges prepaid) to such address and to the attention of such person as the recipient party has specified by prior written notice to the sending party. Notices will be deemed to have
been given hereunder when delivered personally, three business days after deposit in the U.S. mail postage prepaid with return receipt requested and two business days after deposit postage prepaid with a reputable overnight courier service for
delivery on the next business day. 
 Section 4.5 Entire Agreement. This Agreement, the Transaction
Documents (other than any Other Agreements) and any documents and agreements executed in connection with the Exchange and Purchase embody the entire agreement and understanding of the parties hereto with respect to the subject matter hereof and
supersede all prior and contemporaneous oral or written agreements, representations, warranties, contracts, correspondence, conversations, memoranda and understandings between or among the parties or any of their agents, representatives or
affiliates relative to such subject matter, including, without limitation, any term sheets, emails or draft documents. 

Section 4.6 Severability. If any one or more of the provisions contained herein, or the application thereof in any
circumstance, is held invalid, illegal or unenforceable, the validity, legality and enforceability of any such provision in every other respect and of the remaining provisions contained herein shall not be affected or impaired thereby. 

Section 4.7 Construction. References in the singular shall include the plural, and vice versa, unless the context
otherwise requires. References in the masculine shall include the feminine and neuter, and vice versa, unless the context otherwise requires. Headings in this Agreement are for convenience of reference only and shall not limit or otherwise affect
the meanings of the provisions hereof. Neither party, nor its respective counsel, shall be deemed the drafter of this Agreement for purposes of construing the provisions of this Agreement, and all language in all parts of this Agreement shall be
construed in accordance with its fair meaning, and not strictly for or against either party. 

  
 Page 7 of 13

 Section 4.8 Governing Law. This Agreement shall in all respects be
construed in accordance with and governed by the substantive laws of the State of New York, without reference to its choice of law rules. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in
The City of New York, Borough of Manhattan, for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit,
action or proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is brought in an inconvenient forum or that the venue of such suit, action or proceeding is improper.

 Section 4.9 Waiver of Jury Trial. Each party hereby agrees to waive any right to a trial by jury in any
proceeding or counterclaim (whether based upon contract, tort or otherwise) with respect to any claim, counter-claim or action arising out of or in connection with this Agreement or the transactions contemplated hereby (including, without
limitation, the Exchange and Purchase. 
 Section 4.10 Counterparts. This Agreement may be executed in
counterparts, each of which shall be deemed an original, but all of which taken together shall constitute one and the same instrument. Any counterpart or other signature hereon delivered by facsimile shall be deemed for all purposes as constituting
good and valid execution and delivery of this Agreement by such party. 
 [Signature Page Follows] 

  
 Page 8 of 13

 IN WITNESS WHEREOF, each of the parties hereto has caused this Agreement to be executed as
of the date first above written. 
  

			
	SAVIENT PHARMACEUTICALS, INC.
		
	By:	 	 
	Name:	 	
	Title:	 	

  

			
	[HOLDER’S LEGAL NAME]
		
	By:	 	 
	Name:	 	
	Title:	 	

  
 Page 9 of 13

 EXHIBIT A 
 Form of Indenture 

  
 Page 10 of 13

 EXHIBIT B 
 Form of Company Counsel Opinion 
 [Attached] 

  
 Page 11 of 13

 EXHIBIT C 
 Exchanging Beneficial Owners 
  

											
	 Name of
 Beneficial Owner
	  	DTC
Participant /
Broker Contact
Name and
Phone Number	  	Broker DTC
Participant #	  	Principal
Amount
of Exchanged
Existing Notes
(CUSIP
80517QAA8)	  	Principal
Amount of
Exchanged
New Notes
(CUSIP
80517Q142)	  	Cash Interest
Payment

  
 Page 12 of 13

 EXHIBIT D 
 Purchasing Beneficial Owners 
  

							
	 Name of
 Beneficial Owner
	  	DTC Participant
Contact Name and
Phone Number	  	DTC Participant #	  	Principal Amount of Purchased New
Notes (CUSIP 80517Q142)

  
 Page 13 of 13Pledge and Security Agreement

 Exhibit 10.2 
 PLEDGE AND SECURITY AGREEMENT 
 dated as of May 9, 2012

 by and among 
 SAVIENT PHARMACEUTICALS, INC., 
 EACH OF THE OTHER GRANTORS PARTY HERETO

 and 
 U.S. BANK NATIONAL ASSOCIATION, 
 as Collateral Agent 

 TABLE OF CONTENTS 

 

							
	 	 	 	  	PAGE	 
	 SECTION 1.
	 	DEFINITIONS; GRANT OF SECURITY	  	 	1	  
			
	 1.1
	 	General Definitions	  	 	1	  
	 1.2
	 	Definitions; Interpretation	  	 	5	  
			
	 SECTION 2.
	 	GRANT OF SECURITY	  	 	5	  
			
	 2.1
	 	Grant of Security	  	 	5	  
	 2.2
	 	Certain Limited Exclusions	  	 	6	  
			
	 SECTION 3.
	 	SECURITY FOR OBLIGATIONS; GRANTORS REMAIN LIABLE	  	 	6	  
			
	 3.1
	 	Security for Obligations	  	 	6	  
	 3.2
	 	Continuing Liability Under Collateral	  	 	6	  
			
	 SECTION 4.
	 	CERTAIN PERFECTION REQUIREMENTS	  	 	7	  
			
	 4.1
	 	Delivery Requirements	  	 	7	  
	 4.2
	 	Control Requirements	  	 	7	  
	 4.3
	 	Intellectual Property Recording Requirements	  	 	8	  
	 4.4
	 	Other Actions	  	 	8	  
			
	 SECTION 5.
	 	REPRESENTATIONS AND WARRANTIES	  	 	8	  
			
	 5.1
	 	Grantor Information & Status	  	 	8	  
	 5.2
	 	Collateral Identification, Special Collateral	  	 	8	  
	 5.3
	 	Ownership of Collateral and Absence of Other Liens	  	 	8	  
	 5.4
	 	Status of Security Interest	  	 	9	  
	 5.5
	 	Pledged Equity Interests, Investment Related Property	  	 	9	  
	 5.6
	 	Secured Obligations	  	 	9	  
			
	 SECTION 6.
	 	COVENANTS AND AGREEMENTS	  	 	9	  
			
	 6.1
	 	Grantor Information and Status	  	 	9	  
	 6.2
	 	Collateral Identification; Special Collateral	  	 	10	  
	 6.3
	 	Impairment of Collateral	  	 	10	  
	 6.4
	 	Status of Security Interest	  	 	10	  
			
	 SECTION 7.
	 	FURTHER ASSURANCES; ADDITIONAL GRANTORS	  	 	10	  
			
	 7.1
	 	Further Assurances	  	 	10	  
	 7.2
	 	Additional Grantors	  	 	11	  
			
	 SECTION 8.
	 	CONCERNING THE COLLATERAL AGENT	  	 	11	  
			
	 8.1
	 	Power of Attorney	  	 	11	  
	 8.2
	 	Duties of the Collateral Agent	  	 	11	  
	 8.3
	 	Rights of the Collateral Agent	  	 	12	  
	 8.4
	 	Individual Rights of Collateral Agent	  	 	13	  
	 8.5
	 	Collateral Agent’s Disclaimer	  	 	13	  
	 8.6
	 	Replacement of Collateral Agent	  	 	13	  
	 8.7
	 	Successor Collateral Agent by Merger, Etc.	  	 	14	  
	 8.8
	 	Eligibility	  	 	14	  
	 8.9
	 	Co-Collateral Agent; Separate Collateral Agent	  	 	14	  
	 8.10
	 	Liability; Enforcement Expenses; Indemnification	  	 	14	  

  
 i 

							
			
	 SECTION 9.
	 	REMEDIES	  	 	15	  
			
	 9.1
	 	Generally	  	 	15	  
	 9.2
	 	Application of Proceeds	  	 	16	  
	 9.3
	 	[Reserved]	  	 	16	  
	 9.4
	 	Investment Related Property	  	 	16	  
	 9.5
	 	Intellectual Property License	  	 	17	  
			
	 SECTION 10.
	 	COLLATERAL AGENT	  	 	17	  
			
	 SECTION 11.
	 	CONTINUING SECURITY INTEREST; TRANSFER OF NOTES	  	 	17	  
			
	 SECTION 12.
	 	MISCELLANEOUS	  	 	17	  
			
	 SECTION 13.
	 	CONFLICTS	  	 	18	  

  

	
	 SCHEDULE 5.4 — FILINGS/FILING OFFICES

	
	 EXHIBIT A — PLEDGE SUPPLEMENT

	
	 EXHIBIT B — UNCERTIFICATED SECURITIES CONTROL AGREEMENT

	
	 EXHIBIT C – IP SECURITY AGREEMENT

	
	 EXHIBIT D – PERFECTION CERTIFICATE

  
 ii 

 This PLEDGE AND SECURITY AGREEMENT, dated as of May 9, 2012 (as it may be
amended, restated, supplemented or otherwise modified from time to time, this “Agreement”), among SAVIENT PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), certain Subsidiaries of the Company
party hereto from time to time, whether as an original signatory hereto or as an Additional Grantor (as herein defined) (together with the Company, each, a “Grantor,” and collectively, the “Grantors”), and U.S.
BANK NATIONAL ASSOCIATION, as collateral agent for the Secured Parties (in such capacity as collateral agent, together with its successors and permitted assigns, the “Collateral Agent”). 

RECITALS: 

WHEREAS, capitalized terms used in these Recitals shall have the respective meanings set forth for such terms in Section 1.1
hereof; 
 WHEREAS, the Company has issued $170,941,000 in aggregate principal amount of the Senior Secured Discount
Notes due 2019 (the “Notes”) pursuant to the indenture dated as of the date hereof (as it may be amended, restated, supplemented or otherwise modified from time to time, the “Indenture”) by and among the
Company, the Grantors and U.S. Bank National Association, as trustee (in such capacity as trustee, together with its successors and permitted assigns in such capacity, the “Trustee”); 

WHEREAS, to induce the purchasers of the Notes to purchase the Notes, each Grantor has agreed to secure the Obligations of each
such Grantor under the Indenture and the Notes with the Collateral; 
 WHEREAS, the parties hereto desire to more fully
set forth their respective rights in connection with such security interest as set forth herein; and 
 NOW, THEREFORE,
in consideration of the premises and the agreements, provisions and covenants herein contained, and for other good and valuable consideration the receipt and sufficiency of which is hereby acknowledged, each Grantor and the Collateral Agent agree as
follows: 
 SECTION 1. DEFINITIONS; GRANT OF SECURITY. 

1.1 General Definitions. In this Agreement, the following terms shall have the following meanings: 

“Account” shall mean any “account” as such term is defined in the UCC, and in any event shall
include but shall not be limited to, all rights to payment of any monetary obligation, whether or not earned by performance, (i) for property that has been or is to be sold, leased, licensed, assigned or otherwise disposed of or (ii) for
services rendered or to be rendered. Without limiting the foregoing, the term “account” shall include all Health-Care-Insurance Receivables. 
 “Additional Grantors” shall have the meaning assigned in Section 7.2. 
 “Agreement” shall have the meaning set forth in the preamble. 
 “ANDA” shall mean an abbreviated new drug application. 
 “Cash Proceeds” shall have the meaning assigned in Section 9.7. 
 “Chattel Paper” shall mean “chattel paper” as such term is defined in the UCC. Without limiting the foregoing, the term “Chattel Paper” shall in any event include all
Tangible Chattel Paper and all Electronic Chattel Paper. 
 “Collateral” shall have the meaning
assigned in Section 2.1. 
 “Collateral Agent” shall have the meaning set forth in the
preamble. 
 “Collateral Records” shall mean books, records, ledger cards, files,
correspondence, customer lists, supplier lists, blueprints, technical specifications, manuals, computer software and related documentation, computer printouts, tapes, disks and other electronic storage media and related data processing software and
similar items that at any time evidence or contain information relating to any of the Collateral or are otherwise necessary or helpful in the collection thereof or realization thereupon. 

  
 1 

 “Collateral Support” shall mean all property (real or
personal) assigned, hypothecated or otherwise securing any Collateral and shall include any security agreement or other agreement granting a Lien or security interest in such real or personal property. 

“Company” shall have the meaning set forth in the preamble. 

“Contracts” shall mean (i) all contracts, agreements, licenses and covenants between any Grantor and
one or more additional parties (including but not limited to purchase orders) and (ii) any NDA and ANDA. 

“Contract Rights” shall mean all rights of any Grantor under each Contract, including, without
limitation, (i) any and all rights to receive and demand payments under any or all Contracts, (ii) any and all rights to receive and compel performance under any or all Contracts and (iii) any and all other rights, interests and
claims now existing or in the future arising in connection with any or all Contracts. 

“Control” shall mean: (1) with respect to any Deposit Accounts, control within the meaning of
Section 9-104 of the UCC, (2) with respect to any Securities Accounts, Security Entitlements, Commodity Contract or Commodity Account, control within the meaning of Section 9-106 of the UCC, (3) with respect to any Uncertificated
Securities, control within the meaning of Section 8-106 of the UCC, (4) with respect to any Certificated Security, control within the meaning of Section 8-106 of the UCC, (5) with respect to any Electronic Chattel Paper, control
within the meaning of Section 9-105 of the UCC, (6) with respect to Letter of Credit Rights, control within the meaning of Section 9-107 of the UCC and (7) with respect to any “transferable record” (as that term is
defined in Section 201 of the Federal Electronic Signatures in Global and National Commerce Act or in Section 16 of the Uniform Electronic Transactions Act as in effect in any relevant jurisdiction), control within the meaning of
Section 201 of the Federal Electronic Signatures in Global and National Commerce Act or in Section 16 of the Uniform Electronic Transactions Act as in effect in the jurisdiction relevant to such transferable record. 

“Copyright Licenses” shall mean any and all Contracts providing for the granting of any right in or to
any Copyright or otherwise providing for a covenant not to sue for infringement or other violation of any Copyright (whether such Grantor is licensee or licensor thereunder), including, without limitation, the agreements required to be set forth on
Schedule 7(c) to the Perfection Certificate under the heading “Copyright Licenses”. 

“Copyrights” shall mean all United States, and foreign copyrights (whether or not the underlying works of
authorship have been published), including but not limited to copyrights in software and all rights in and to databases, all designs (including but not limited to industrial designs, Protected Designs within the meaning of 17 U.S.C. 1301 et.
Seq. and Community designs), and all Mask Works (as defined under 17 U.S.C. 901 of the U.S. Copyright Act), whether registered or unregistered, as well as all reversionary interests, and termination rights, and, with respect to any and all
of the foregoing: (i) all registrations and applications therefor including, without limitation, the registrations and applications required to be listed in Schedule 7(b) to the Perfection Certificate, (ii) all extensions and
renewals thereof, and (iii) all other rights of any kind accruing thereunder throughout the world. 

“Domain Names” shall mean all internet domain names and associated URL addresses in or to which any
Grantor now or hereafter has any right, title or interest. 
 “Equipment” shall mean any
“equipment” as such term is defined in the UCC, and in any event, shall include, but shall not be limited to, all machinery, equipment, furnishings, fixtures and vehicles now or hereafter owned by any Grantor and any and all additions,
substitutions and replacements of any of the foregoing and all accessions thereto, wherever located, together with all attachments, components, parts, equipment and accessories installed thereon or affixed thereto. 

“Excluded Assets” shall have the meaning as specified in the Indenture. 

“First Priority” shall mean, with respect to any Lien purported to be created in any Collateral pursuant
to any Collateral Document, that such Lien is senior to all other Liens with respect to all Collateral and such Collateral is not subject to any Liens other than Permitted Liens. 

“Grantor” and “Grantors” shall have the meaning set forth in the preamble.

 “Indenture” shall have the meaning set forth in the preamble. 

“Insurance” shall mean all insurance policies covering any or all of the Collateral (regardless of
whether the Collateral Agent is the loss payee thereof). 

  
 2 

 “Intellectual Property” shall mean, the collective
reference to all rights relating to intellectual property, whether arising under the United States, multinational or foreign laws or otherwise, including without limitation, Copyrights, Patents, Domain Names, Trademarks, Trade Secrets, Trade Secret
Rights, and all rights under Copyright Licenses, Patent Licenses, Trademark Licenses and Trade Secret Licenses, and the right to sue or otherwise recover for any past, present and future infringement, dilution, misappropriation, or other violation
or impairment thereof, including the right to receive all Proceeds therefrom, including without limitation license fees, royalties, income, payments, claims, damages and proceeds of suit, now or hereafter due and/or payable with respect thereto.

 “Intellectual Property Security Agreement” shall mean each intellectual property security
agreement executed and delivered by the applicable Grantors, substantially in the form set forth in Exhibit C. 
 “Inventory” shall mean merchandise, inventory and goods, and all additions, substitutions and replacements thereof and all accessions thereto, wherever located, together with all goods,
supplies, incidentals, packaging materials, labels, materials and any other items used or usable in manufacturing, processing, packaging or shipping same, in all stages of production from raw materials through work in process to finished goods, and
all products and proceeds of whatever sort and wherever located any portion thereof which may be returned, rejected, reclaimed or repossessed by the Collateral Agent from any Grantor’s customers, and shall specifically include all
“inventory” as such term is defined in the UCC. 
 “Investment Accounts” shall mean
the Securities Accounts, Commodity Accounts and Deposit Accounts. 
 “Investment Related
Property” shall mean: (i) all “investment property” (as such term is defined in Article 9 of the UCC) and (ii) all of the following (regardless of whether classified as investment property under the UCC): all
Pledged Equity Interests, Pledged Debt, the Investment Accounts and certificates of deposit. 
 “Material
Intellectual Property” shall mean any Intellectual Property included in the Collateral that the Company has determined in its reasonable business judgment is material to the business of the Company and its Subsidiaries, taken as a whole.

 “NDA” shall mean a new drug application. 

“Notes” shall have the meaning set forth in the preamble. 

“Patent Licenses” shall mean all Contracts providing for the granting of any right in or to any Patent or
otherwise providing for a covenant not to sue for infringement or other violation of any Patent (whether such Grantor is licensee or licensor thereunder), including, without limitation, the agreements required to be set forth on Schedule 7(c)
to the Perfection Certificate under the heading “Patent Licenses”. 
 “Patents” shall
mean all United States and foreign patents and certificates of invention, or similar industrial property rights, and applications for any of the foregoing, including, without limitation: (i) each patent and patent application required to be
listed in Schedule 7(a) to the Perfection Certificate under the headings “United States Patents” and “Other Patents”, (ii) all reissues, divisionals, continuations, continuations-in-part, extensions, renewals, and
reexaminations thereof, and (iii) all other rights of any kind accruing thereunder throughout the world. 

“Perfection Certificate” shall mean a certificate substantially in the form of Exhibit D, dated
the date hereof, completed and supplemented with the schedules and attachments contemplated thereby, and duly executed by an Officer of each of the Grantors. 
 “Permits” shall mean, to the extent permitted to be assigned by the terms thereof or by applicable law, all licenses, permits, rights, orders, variances, franchises or authorizations of
or from any governmental authority or agency (including but not limited to, all ANDAs and NDAs approved by the United States Food and Drug Administration). 
 “Pledge Supplement” shall mean any supplement to this Agreement in substantially the form of Exhibit A. 

“Pledged Debt” shall mean all third-party indebtedness for borrowed money owed to such Grantor, whether
or not evidenced by any Instrument, including, without limitation, all indebtedness described on Schedule 6 to the Perfection Certificate, issued by the obligors named therein, the instruments, if any, evidencing any of the foregoing, and all
interest, cash, instruments and other property or proceeds from time to time received, receivable or otherwise distributed in respect of or in exchange for any or all of the foregoing. 

  
 3 

 “Pledged Equity Interests” shall mean all Pledged Stock and
any other participation or interests in any equity or profits of any business entity including, without limitation, any trust and all management rights relating to any entity whose equity interests are included as Pledged Equity Interests.

 “Pledged Stock” shall mean all shares of capital stock owned by such Grantor, including,
without limitation, all equity interests described on Schedule 5 to the Perfection Certificate, and the certificates, if any, representing such equity interests and any interest of such Grantor in the entries on the books of the issuer
of such shares or on the books of any securities intermediary pertaining to such shares, and all dividends, distributions, cash, warrants, rights, options, instruments, securities and other property or proceeds from time to time received, receivable
or otherwise distributed in respect of or in exchange for any or all of such equity interest other than any such interests which constitute Excluded Assets, or are otherwise excluded from the Collateral pursuant to Section 2.2 hereof.

 “Receivables” shall mean all rights to payment, whether or not earned by performance, for
goods or other property sold, leased, licensed, assigned or otherwise disposed of, or services rendered or to be rendered, including, without limitation all such rights constituting or evidenced by any Account, Chattel Paper, Instrument, General
Intangible, Investment Related Property or Letter of Credit Rights, together with all of Grantor’s rights, if any, in any goods or other property giving rise to such right to payment and all Collateral Support and Supporting Obligations related
thereto and all Receivables Records. 
 “Receivables Records” shall mean (i) all original
copies of all documents, instruments or other writings or electronic records or other Records evidencing the Receivables, (ii) all books, correspondence, credit or other files, Records, ledger sheets or cards, invoices, and other papers
relating to Receivables, including, without limitation, all tapes, cards, computer tapes, computer discs, computer runs, record keeping systems and other papers and documents relating to the Receivables, whether in the possession or under the
control of Grantor or any computer bureau or agent from time to time acting for Grantor or otherwise, (iii) all evidences of the filing of financing statements and the registration of other instruments in connection therewith, and amendments,
supplements or other modifications thereto, notices to other creditors, secured parties or agents thereof, and certificates, acknowledgments, or other writings, including, without limitation, Lien search reports, from filing or other registration
officers, (iv) all credit information, reports and memoranda relating thereto and (v) all other written or non-written forms of information related in any way to the foregoing or any Receivable. 

“Secured Obligations” shall have the meaning assigned in Section 3.1. 

“Securities” shall mean any stock, shares, partnership interests, voting trust certificates, certificates
of interest or participation in any profit-sharing agreement or arrangement, options, warrants, bonds, debentures, notes, or other evidences of indebtedness, secured or unsecured, convertible, subordinated or otherwise, or in general any instruments
commonly known as “securities” or any certificates of interest, shares or participations in temporary or interim certificates for the purchase or acquisition of, or any right to subscribe to, purchase or acquire, any of the foregoing.

 “Trademark Licenses” shall mean any and all Contracts providing for the granting of any right
in or to any Trademark or otherwise providing for a covenant not to sue for infringement, dilution or other violation of any Trademark or permitting co-existence with respect to a Trademark (whether such Grantor is licensee or licensor thereunder),
including, without limitation, the agreements required to be set forth on Schedule 7(c) to the Perfection Certificate under the heading “Trademark Licenses”. 

“Trademarks” shall mean all United States, and foreign trademarks, trade names, trade dress, corporate
names, company names, business names, fictitious business names, service marks, certification marks, collective marks, logos, other source or business identifiers and designs, whether or not registered, and with respect to any and all of the
foregoing: (i) all registrations and applications therefor including, without limitation, the registrations and applications required to be listed in Schedule 7(a) to the Perfection Certificate under the headings “United States
Trademarks” and “Other Trademarks”, (ii) all extensions or renewals of any of the foregoing, (iii) all of the goodwill of the business connected with the use of and symbolized by any of the foregoing, and (iv) all other
rights of any kind accruing thereunder throughout the world. 
 “Trade Secret Licenses” shall
mean any and all Contracts providing for the granting of any right in or to Trade Secrets (whether such Grantor is licensee or licensor thereunder). 

  
 4 

 “Trade Secrets” shall mean all trade secrets and all other
confidential or proprietary information and know-how, whether or not the foregoing has been reduced to a writing or other tangible form, including all documents and things embodying, incorporating, or referring in any way to the foregoing, and all
other similar rights of any kind accruing thereunder throughout the world. 
 “Trade Secret
Rights” shall mean the rights of any Grantor in any Trade Secret it holds. 
 “Trustee”
shall have the meaning set forth in the preamble. 
 “UCC” shall mean the
Uniform Commercial Code as in effect from time to time in the State of New York; provided, however, that in the event that, by reason of mandatory provisions of law, any or all of the perfection or priority of, or remedies with respect to, any
Collateral is governed by the Uniform Commercial Code as enacted and in effect in a jurisdiction other than the State of New York, the term “UCC” shall mean the Uniform Commercial Code as enacted and in effect in such other
jurisdiction solely for purposes of the provisions hereof relating to such perfection, priority or remedies. 

“United States” shall mean the United States of America. 

1.2 Definitions; Interpretation. All capitalized terms used herein (including the preamble and recitals hereto) and
not otherwise defined herein shall have the meanings ascribed thereto in the Indenture or the UCC (as in effect on the date hereof). The incorporation by reference of terms defined in the Indenture shall survive any termination of the Indenture
until this Agreement is terminated as provided in Section 11 hereof. Any of the terms defined herein may, unless the context otherwise requires, be used in the singular or the plural, depending on the reference. References herein to any
Section, Appendix, Schedule or Exhibit shall be to a Section, an Appendix, a Schedule or an Exhibit, as the case may be, hereof unless otherwise specifically provided. The use herein of the word “include” or “including”, when
following any general statement, term or matter, shall not be construed to limit such statement, term or matter to the specific items or matters set forth immediately following such word or to similar items or matters, whether or not non-limiting
language (such as “without limitation” or “but not limited to” or words of similar import) is used with reference thereto, but rather shall be deemed to refer to all other items or matters that fall within the broadest possible
scope of such general statement, term or matter. The terms lease and license shall include sub-lease and sub-license, as applicable. All references herein to provisions of the UCC shall include all successor provisions under any subsequent version
or amendment to any Article of the UCC. 
 SECTION 2. GRANT OF SECURITY. 

2.1 Grant of Security. Subject to Section 2.2, each Grantor hereby grants to the Collateral Agent, for the
benefit of the Secured Parties, a security interest in all of such Grantor’s respective right, title and interest in, to and under all the following property interests and assets of any kind, nature or in any form whatsoever, of such Grantor,
in each case whether now or hereafter existing or in which any Grantor now has or hereafter acquires an interest and wherever the same may be located (all of which being hereinafter collectively referred to as the “Collateral”):

 (a) each and every Account; 

(b) all cash, Cash Equivalents and Investments; 

(c) all Chattel Paper and promissory notes; 

(d) all Commercial Tort Claims now or hereafter in existence, including such claims described on Schedule 8 to the
Perfection Certificate; 
 (e) all Domain Names and Trade Secret Rights; 

(f) all Contracts, together with all Contract Rights; 

(g) all Intellectual Property; 
 (h) all Equipment; 
 (i) all Securities Accounts, Deposit Accounts
and all other demand, deposit, time, savings, cash management, passbook and similar accounts maintained by, or for the benefit of, such Grantor with any person and all monies, securities, Instruments and other investments deposited or required to be
deposited in any of the foregoing; 
 (j) all Documents; 

(k) all General Intangibles; 

  
 5 

 (l) all Goods; 

(m) all Instruments; 
 (n) all Inventory; 
 (o) all Financial Assets and Investment
Related Property; 
 (p) all Letter-of-Credit Rights (whether or not the respective letter of credit is evidenced
by a writing); 
 (q) all Permits; 

(r) all Software and all Software licensing rights, all writings, plans, specifications and schematics, all engineering
drawings, customer lists, goodwill and licenses, and all recorded data of any kind or nature, regardless of the medium of recording; 
 (s) all Supporting Obligations; 
 (t) all intercompany claims
(including, without limitations, claims arising from the distribution by the Company of proceeds of the Notes); 

(u) all Securities and all options and warrants to purchase Securities; 

(v) all NDAs and ANDAs; 
 (w) all Insurance; 
 (x) all Receivables and Receivables Records;

 (y) all Security Entitlements in any of the foregoing; 

(z) to the extent not otherwise included above, all Collateral Records, Collateral Support and Supporting Obligations
relating to any and all of the foregoing; and 
 (aa) to the extent not otherwise included above, all Proceeds,
products, accessions, rents and profits of or in respect of any and all of the foregoing. 
 2.2 Certain
Limited Exclusions. 
 (a) Notwithstanding anything herein or the Indenture to the contrary, the
security interest created by this Agreement shall not extend to, and the term Collateral shall not include, any Excluded Assets. 
 (b) Notwithstanding anything herein to the contrary, in no event will the Collateral include and no Grantor will be deemed to have granted a security interest in any of its right, title or interest
in any trademark application filed on an “intent to use” basis until such time as a statement of use has been filed with and duly accepted by the United States Patent and Trademark Office. 

(c) Notwithstanding anything herein or in the Indenture to the contrary, no Grantor shall be required to pledge or create
a security interest in any Capital Stock or other equity interests of any Foreign Subsidiary to the extent such action (i) violates applicable law (including corporate benefit, financial assistance, fraudulent preference, thin capitalization
rules and similar laws or regulations which limit the ability to provide collateral security on local assets or properties) and/or (ii) would reasonably be expected to violate or conflict with any fiduciary duties of officers or directors of
such Foreign Subsidiary or result in a risk of personal or criminal liability of any officer or director of such Foreign Subsidiary, in each case as certified to the Collateral Agent by an officer of the Issuer. 

SECTION 3. SECURITY FOR OBLIGATIONS; GRANTORS REMAIN LIABLE. 

3.1 Security for Obligations. The Collateral is collateral security for, the prompt and complete payment or
performance in full when due, whether at stated maturity, by required prepayment, declaration, acceleration, demand or otherwise, of all Obligations with respect to the Securities (as defined in the Indenture) (the “Secured
Obligations”). 
 3.2 Continuing Liability Under Collateral. Notwithstanding anything
herein to the contrary, (i) each Grantor shall remain liable for all obligations it may have in respect of any portion of the Collateral in which it may have obligations and nothing contained herein is intended or shall be a delegation of
duties to the Collateral Agent or any other Secured Party, (ii) each Grantor shall remain liable under each of the agreements included in the Collateral to perform all of the obligations 

  
 6 

 
undertaken by it thereunder all in accordance with and pursuant to the terms and provisions thereof, (iii) neither the Collateral Agent nor any Secured Party shall have any obligation or
liability under any Collateral or under each of the agreements included in the Collateral by reason of or arising out of this Agreement or any other document related thereto nor shall the Collateral Agent nor any Secured Party have any obligation to
make any inquiry as to the nature or sufficiency of any payment received by it, have any obligation to take any action to collect or enforce any rights under any agreement included in the Collateral or have any obligation to verify or monitor
compliance by such Grantor or other party under such agreements and (iv) the exercise by the Collateral Agent of any of its rights hereunder shall not release any Grantor from any of its duties or obligations under the contracts and agreements
included in the Collateral. 
 SECTION 4. CERTAIN PERFECTION REQUIREMENTS 

4.1 Delivery Requirements 
 (a) With respect to any Certificated Securities included in the Collateral, each Grantor shall promptly (in any case, by no later than the time otherwise required hereunder and under the Indenture)
deliver to the Collateral Agent the Security Certificates evidencing such Certificated Securities duly indorsed by an effective indorsement (within the meaning of Section 8-107 of the UCC), or accompanied by share transfer powers or other
instruments of transfer duly endorsed by such an effective endorsement, in each case, to the Collateral Agent or in blank. 
 (b) With respect to any Instruments or Tangible Chattel Paper included in the Collateral, each Grantor shall promptly (in any case, by no later than the time otherwise required hereunder and under the
Indenture) deliver to the Collateral Agent all such Instruments or Tangible Chattel Paper to the Collateral Agent duly indorsed in blank. 
 4.2 Control Requirements 
 (a) With respect to any Deposit
Accounts, Securities Accounts, Security Entitlements, Commodity Accounts and Commodity Contracts included in the Collateral, each Grantor shall, within the time period specified in the Indenture for any such Investment Account, Commodity Contracts
and Security Entitlement existing on the Issue Date, and within 90 days of the opening of any such Investment Account, Commodity Contracts and Security Entitlement after the Issue Date, ensure that the Collateral Agent has Control thereof.
With respect to any such Securities Accounts or Securities Entitlements, such Control shall be accomplished by the Grantor causing the Securities Intermediary maintaining such Securities Account or Security Entitlement to enter into an agreement in
substance reasonably satisfactory to the Collateral Agent, within the time periods as specified in the preceding sentence, so that any such Securities Intermediary shall comply with the Collateral Agent’s Entitlement Orders without further
consent by such Grantor. With respect to any such Deposit Account, each Grantor shall, within the time periods specified in the first sentence of this Section 4.2(a), cause the depositary institution maintaining such account to enter
into an agreement in substance reasonably satisfactory to the Collateral Agent pursuant to which the Bank shall agree to comply with the Collateral Agent’s instructions with respect to disposition of funds in the Deposit Account without further
consent by such Grantor. 
 (b) With respect to any Uncertificated Security with a Fair Market Value in excess of
$500,000, included in the Collateral (other than any Uncertificated Securities credited to a Securities Account) each Grantor shall cause the issuer of such Uncertificated Security to either promptly (i) register the Collateral Agent as the
registered owner thereof on the books and records of the issuer or (ii) execute an agreement substantially in the form of Exhibit B hereto pursuant to which such issuer shall agree to comply with the Collateral Agent’s
instructions with respect to disposition of funds in the Uncertificated Security without further consent by such Grantor. 
 (c) With respect to any Letter of Credit Rights with a Fair Market Value in excess of $500,000 included in the Collateral (other than any Letter of Credit Rights constituting a Supporting Obligation for a
Receivable in which the Collateral Agent has a valid and perfected security interest), each Grantor shall use its commercially reasonable efforts to obtain the written consent of each issuer of each related letter of credit to the assignment of the
proceeds of such letter of credit to the Collateral Agent. 
 (d) With respect any Electronic Chattel Paper with
a Fair Market Value in excess of $500,000 or “transferable record” (as that term is defined in Section 201 of the Federal Electronic Signatures in Global and National Commerce Act or in Section 16 of the Uniform Electronic
Transactions Act as in effect in any relevant jurisdiction) included in the Collateral, each Grantor shall use commercially reasonable efforts to ensure that the Collateral Agent has Control thereof. 

  
 7 

 4.3 Intellectual Property Recording Requirements. In the case of any
material Collateral (whether now owned or hereafter acquired) consisting of issued U.S. patents, U.S. federally registered trademarks, and, in each case, pending applications therefor, U.S. copyright registrations and exclusive Copyright
Licenses in respect of U.S. registered copyrights for which any Grantor is the licensee, each Grantor shall execute and deliver to the Collateral Agent an Intellectual Property Security Agreement substantially in the form of Exhibit C
hereto and, by no later than 60 days after the end of each fiscal quarter, a supplement thereto covering all such patents, trademarks and pending applications therefore and copyrights and copyright licenses (in each case, to the extent not
already covered by such previous Intellectual Property Security Agreement or supplements thereto) in appropriate form for recordation with the U.S. Patent and/or U.S. Copyright Office, as applicable, with respect to the security interest of the
Collateral Agent. The Collateral Agent shall file any such recordation with the offices where the Grantor directs the Collateral Agent to file such recordations, at the Company’s expense, but the Collateral Agent shall not be responsible for
correcting any errors or defects in such recordations or for attempting to refile any recordations not accepted for filing by the offices where such Grantor directs such filings to be made, and the Collateral Agent assumes no responsibility for the
content of any such filings. 
 4.4 Other Actions 

(a) Subject to the Indenture and Section 2.2 hereof, if any issuer of any Pledged Equity Interest that is not
otherwise an Excluded Asset is organized under a jurisdiction outside of the United States, each Grantor shall take, within the time periods specified in Section 9.04 of the Indenture, such additional actions which are necessary (or are
otherwise reasonably requested by the Collateral Agent), which may include, without limitation, causing the issuer to register the required pledge (if any) on its books and records or making such filings or recordings, in each case as may be
necessary or advisable, under the laws of such issuer’s jurisdiction to insure the validity, perfection and priority of the security interest of the Collateral Agent. 
 SECTION 5. REPRESENTATIONS AND WARRANTIES. 
 As of the date
hereof, each Grantor hereby represents and warrants that: 
 5.1 Grantor Information & Status

 The Perfection Certificate has been duly prepared, completed and executed, and the information set forth
therein is correct and complete in all material respects as of the date hereof. 
 5.2 Collateral
Identification, Special Collateral 
 (a) No material portion of the Collateral constitutes, or is the
Proceeds of, (1) Farm Products, (2) As-Extracted Collateral, (3) Manufactured Homes, (4) Health-Care-Insurance Receivables; (5) timber to be cut, or (6) aircraft, aircraft engines, satellites, ships or railroad rolling
stock. No material portion of the Collateral consists of motor vehicles or other goods subject to a certificate of title statute of any jurisdiction; and 
 (b) all written information supplied by any Grantor to the Trustee and Collateral Agent with respect to the Collateral taken as a whole is accurate and complete in all material respects. 

5.3 Ownership of Collateral and Absence of Other Liens 

(a) The respective rights of each Grantor in the Collateral are free and clear of any and all Liens, rights or claims of
all other Persons other than any Permitted Liens; and 
 (b) other than any financing statements filed in favor
of the Collateral Agent, no effective financing statement, fixture filing or other instrument similar in effect under any applicable law covering all or any material part of the Collateral is on file in any filing or recording office except for
(x) financing statements for which duly authorized proper termination statements have been filed and (y) financing statements filed in connection with Permitted Liens. Other than the Collateral Agent and any automatic control in favor of a
Bank, Securities Intermediary or Commodity Intermediary maintaining a Deposit Account, Securities Account or Commodity Contract, no Person (other than the Collateral Agent) is in Control of any material portion of the Collateral (other than with
respect to any bank accounts of the Grantors which are not subject to the control of the Collateral Agent pursuant to the terms of the Collateral Documents or as otherwise permitted under the Indenture). 

  
 8 

 5.4 Status of Security Interest 

(a) Upon the filing of financing statements naming each Grantor as “debtor” and the Collateral Agent as
“secured party” and describing the Collateral as “all assets of the debtor, whether now existing or hereafter arising” in the filing offices set forth opposite such Grantor’s name on Schedule 5.4 hereof, the
security interest of the Collateral Agent in all Collateral that can be perfected by the filing of such financing statements under the UCC as in effect in such jurisdictions will constitute a valid and perfected security interest in such Collateral,
prior to any other Lien on such Collateral other than any Permitted Liens. Each agreement purporting to give the Collateral Agent Control over any Collateral is effective to establish the Collateral Agent’s Control of the Collateral subject
thereto; 
 (b) to the extent perfection or priority of the security interest therein is not subject to
Article 9 of the UCC, and upon recordation of the security interests granted pursuant to the Intellectual Property Security Agreements in the U.S. Patent and Trademark Office and the U.S. Copyright Office, the security interests
granted to the Collateral Agent hereunder shall constitute valid, perfected, First Priority Liens in the United States with respect to the Intellectual Property identified in the schedules to such Intellectual Property Security Agreements (subject
to Permitted Liens); and 
 (c) no authorization, consent, approval or other action by, and no notice to or
filing with, any governmental authority or regulatory body or any other Person is required, other than the filing of financing statements and recordations at the US Patent and Trademark Office and US Copyright Office, for either (i) the pledge
or grant by any Grantor of the Liens purported to be created in favor of the Collateral Agent hereunder or (ii) the exercise by Collateral Agent of any rights or remedies in respect of any Collateral (whether specifically granted or created
hereunder or created or provided for by applicable law), except (A) for the filings contemplated by Section 5.4(a) above or (B) as may be required, in connection with the disposition of any Investment Related Property, by laws
generally affecting the offering and sale of Securities. 
 5.5 Pledged Equity Interests, Investment Related
Property 
 (a) At the Issue Date, such Grantor is the record and beneficial owner of the Pledged Equity
Interests free of all Liens (other than Permitted Liens), rights or claims of other Persons and there are no outstanding warrants, options or other rights to purchase, or shareholder, voting trust or similar agreements outstanding with respect to,
or property that is convertible into, or that requires the issuance or sale of, any Pledged Equity Interests; and 
 (b) at the Issue Date, no consent of any Person including any other general or limited partner, any other member of a limited liability company, any other shareholder or any other trust beneficiary is
necessary in connection with the creation, perfection or priority status of the security interest (except for any Permitted Lien) of the Collateral Agent in any Pledged Equity Interests or the exercise by the Collateral Agent of the voting or other
rights provided for in this Agreement or the exercise of remedies in respect thereof except such as have been obtained. 
 5.6 Secured Obligations 
 The provisions of this Agreement,
together with completion of the actions specified herein and in the Indenture, are effective to create in favor of the Collateral Agent, for the benefit of the Secured Parties, legal, and valid security interests (having the priority provided for
herein (subject to Permitted Liens)) in all right, title and interest in the Collateral in which each Grantor has rights, enforceable against each Grantor. 
 SECTION 6. COVENANTS AND AGREEMENTS. 
 As long as the Secured Obligations
remain outstanding (other than contingent obligations not yet due and payable) each Grantor hereby covenants and agrees (which covenants and agreements shall survive the execution and delivery of this Agreement) that: 

6.1 Grantor Information and Status. The Company shall promptly notify the Collateral Agent of any change in any of
the information provided in the schedules to the Perfection Certificate by supplementing the appropriate schedule thereto and the Company shall take (and the Collateral Agent shall cooperate with the Company to the extent necessary) all actions
reasonably necessary or advisable to maintain the continuous validity, perfection and the same or better priority of the Collateral Agent’s security interest in the Collateral granted or intended to be granted and agreed to hereby, which in the
case of any merger or other change in corporate structure shall include, without limitation, executing and delivering to the Collateral Agent a completed Pledge Supplement together with all supplements to schedules thereto, promptly upon completion
of such merger or other change in corporate structure confirming the grant of the security interest hereunder. 

  
 9 

 6.2 Collateral Identification; Special Collateral 

(a) In the event that it hereafter acquires any material Collateral of a type described in Schedules 5, 6, 7, 8, 9 and 10
to the Perfection Certificate, it shall (i) with respect to Collateral of the type specified in Section 4.3, comply with the terms of Section 4.3 with respect hereto and (ii) with respect to other Collateral described in
Schedules 5, 6, 7, 8, 9 and 10 to the Perfection Certificate notify the Collateral Agent thereof in writing by no later than 60 days after the end of the next occurring fiscal quarter and take such actions and execute such documents at
such time in order to ensure that the Collateral Agent has a valid, perfected, First Priority security interest in such Collateral, subject to Permitted Liens. 
 (b) In the event that it hereafter acquires or has any Commercial Tort Claim in excess of $500,000 it shall promptly deliver to the Collateral Agent a completed Pledge Supplement together with all
supplements to schedules thereto, identifying such new Commercial Tort Claims. 
 6.3 Impairment of
Collateral. The applicable Grantor shall promptly notify the Collateral Agent if any material portion of the Collateral is damaged or destroyed or otherwise impaired or adversely affected. 

6.4 Status of Security Interest. Subject to the terms of the Indenture, this Agreement and the other Collateral
Documents, each Grantor shall maintain the security interest of the Collateral Agent hereunder in all material Collateral as a valid and perfected security interest, prior to any other Lien on such Collateral other than any Permitted Liens.

 SECTION 7. FURTHER ASSURANCES; ADDITIONAL GRANTORS. 

7.1 Further Assurances 
 (a) Subject to this Agreement and the Indenture, each Grantor agrees that from time to time, at the expense of such Grantor, that it shall promptly execute and deliver all further instruments and
documents, and take all further action, that may be reasonably necessary in order to create and/or maintain the validity, perfection or priority of and protect any security interest granted or purported to be granted hereby or to enable the
Collateral Agent to exercise and enforce its rights and remedies hereunder with respect to any Collateral. Without limiting the generality of the foregoing, each Grantor shall: 

(i) file such financing or continuation statements, or amendments thereto, record security interests in Intellectual
Property included in the Collateral and execute and deliver such other agreements, instruments, endorsements, powers of attorney or notices, in order to effect, reflect, perfect and preserve the security interests granted or purported to be granted
hereby; 
 (ii) take all actions reasonably necessary to ensure the recordation of appropriate evidence of the
Liens and security interest granted hereunder in any Intellectual Property included in the Collateral with the U.S. Patent and Trademark Office or the U.S. Copyright Office; and 

(iii) appear in and defend (or take such other actions as the Company reasonably determines are appropriate) any action
or proceeding that could reasonably be expected to materially adversely affect such Grantor’s title to or the Collateral Agent’s security interest in all or any material part of the Collateral. 

(b) Without limiting the foregoing, each Grantor hereby authorizes, at the expense of the Company, the Collateral Agent to
file a Record or Records, including, without limitation, financing or continuation statements, Intellectual Property Security Agreements and amendments and supplements to any of the foregoing, in any jurisdictions and with any filing offices as are
reasonably necessary or advisable to perfect or otherwise protect the security interest granted to the Collateral Agent herein. Such financing statements may describe the Collateral in the same manner as described herein or may contain an indication
or description of collateral that describes such property in any other manner as is necessary to ensure the perfection of the security interest in the Collateral granted to the Collateral Agent herein, including, without limitation, describing such
property as “all assets, whether now owned or hereafter acquired, developed or created” or words of similar effect. 
 (c) Each Grantor hereby authorizes the Collateral Agent to enter into a modification of this Agreement prepared by the Company, including Schedule 5.4, after obtaining any supplement to the
Perfection Certificate as set forth in Section 6.1. 

  
 10 

 7.2 Additional Grantors. In accordance with Section 4.24
of the Indenture, from time to time subsequent to the date hereof, additional Persons may become parties hereto as additional Grantors (each, an “Additional Grantor”), by executing a Pledge Supplement. Upon delivery of any such
Pledge Supplement to the Collateral Agent, notice of which is hereby waived by Grantors, each Additional Grantor shall be a Grantor and shall be as fully a party hereto as if such Additional Grantor were an original signatory hereto, including by
providing a supplement to the Perfection Certificate as set forth in Section 6.1. Each Grantor expressly agrees that its Obligations arising hereunder shall not be affected or diminished by the addition or release of any other Grantor
hereunder. This Agreement shall be fully effective as to any Grantor that is or becomes a party hereto regardless of whether any other Person becomes or fails to become or ceases to be a Grantor hereunder. 

SECTION 8. CONCERNING THE COLLATERAL AGENT. 
 8.1 Power of Attorney. Without limiting any of such Grantor’s obligations and duties hereunder, each Grantor hereby irrevocably appoints the Collateral Agent (such appointment being coupled
with an interest) as such Grantor’s attorney-in-fact, with full authority in the place and stead of such Grantor and in the name of such Grantor, the Collateral Agent or otherwise, from time to time (i) to prepare and file any UCC
financing statements against such Grantor as debtor in accordance with the terms of this Agreement and the Indenture, (ii) to prepare, sign, and file for recordation in any intellectual property registry, appropriate evidence of the Lien and
security interest granted herein in any Intellectual Property owned by any Grantor or exclusive Copyright Licenses in respect of U.S. registered Copyrights for which any Grantor is licensee in the name of such Grantor as debtor in accordance
with the terms of this Agreement and the Indenture and (iii) upon the occurrence and during the continuance of an Event of Default, in the Collateral Agent’s discretion to take any appropriate action and to execute any instrument that the
Collateral Agent may deem reasonably necessary or advisable to accomplish the purposes of this Agreement, including, without limitation, the following: 
 (a) to obtain and adjust insurance required to be maintained by such Grantor or paid to the Collateral Agent pursuant to Section 4.09 of the Indenture; 

(b) to ask for, demand, collect, sue for, recover, compound, receive and give acquittance and receipts for monies due and
to become due under or in respect of any of the Collateral; 
 (c) to receive, endorse and collect any drafts or
other instruments, documents and chattel paper in connection with clause (b) above; 
 (d) to file any
claims or take any action or institute any proceedings that the Collateral Agent may deem necessary or desirable for the collection of any of the Collateral or otherwise to enforce the rights of the Collateral Agent with respect to any of the
Collateral; 
 (e) to take or cause to be taken all actions necessary to perform or comply or cause performance
or compliance with the terms of this Agreement, including, without limitation, access to pay or discharge taxes or Liens (other than Permitted Liens) levied or placed upon or threatened against the Collateral, the legality or validity thereof and
the amounts necessary to discharge the same to be determined by the Collateral Agent in its reasonable discretion, any such payments made by the Collateral Agent to become Obligations of such Grantor to the Collateral Agent, due and payable
immediately without demand; and 
 (f) generally to sell, transfer, lease, license, pledge, make any agreement
with respect to or otherwise deal with any of the Collateral as fully and completely as though the Collateral Agent were the absolute owner thereof for all purposes, and to do, at the Collateral Agent’s option and such Grantor’s expense,
at any time or from time to time, all acts and things that the Collateral Agent deems reasonably necessary to protect, preserve or realize upon the Collateral and the Collateral Agent’s security interest therein in order to effect the intent of
this Agreement, all as fully and effectively as such Grantor might do. 
 8.2 Duties of the Collateral
Agent. 
 (a) If an Event of Default has occurred and is continuing and the Collateral Agent has
received written notice thereof from a Grantor or the Trustee, the Collateral Agent may exercise such of the rights and powers vested in it by the Indenture, this Agreement and the other Collateral Documents. The permissive right of the Collateral
Agent to take or refrain from taking any actions enumerated in the Indenture, this Agreement or any other Collateral Document shall not be construed as a duty and the Collateral Agent shall not be subject to any fiduciary or other implied duties of
any kind or nature to any Secured Party, regardless of whether an Event of Default has occurred or is occurring; 

  
 11 

 (b) (i) the contractual duties of the Collateral Agent shall be
determined solely by the express provisions of this Agreement and the Indenture, and the Collateral Agent need perform only those contractual duties that are specifically set forth in the Indenture, this Agreement and the other Collateral Documents
and no others, and no implied covenants or obligations shall be read into the Indenture, this Agreement or the other Collateral Documents against the Collateral Agent; and (ii) in the absence of bad faith on its part, the Collateral Agent may
conclusively rely, as to the truth of the statements and the correctness of the opinions expressed therein, upon Officers’ Certificates or Opinions of Counsel furnished to the Collateral Agent. 

(c) The Collateral Agent may not be relieved from liability for its own gross negligent action, its own grossly negligent
failure to act, or its own willful misconduct, except that: 
 (i) this paragraph does not limit the effect of
paragraph (b) or (e) of this Section 8.2; 
 (ii) the Collateral Agent shall not be liable for
any error of judgment made in good faith by an officer of the Collateral Agent, unless it is proved that the Collateral Agent was grossly negligent in ascertaining the pertinent facts; and 

(iii) the Collateral Agent shall not be liable with respect to any action it takes or omits to take in good faith in
accordance with a direction received by it at the direction of the Secured Parties, or for the method and place of conducting any proceeding for any remedy available to the Collateral Agent, or exercising any trust or power conferred upon the
Collateral Agent, under this Agreement or any other Collateral Document. 
 (d) Whether or not therein expressly
so provided, every provision of this Agreement or any provision of any other Collateral Document that in any way relates to the Collateral Agent is subject to paragraphs (a), (b), (c), (e) and (f) of this Section 8.2. 

(e) No provision of this Agreement or any other Collateral Document shall require the Collateral Agent to expend or risk
its own funds or incur any liability. 
 (f) The Collateral Agent shall not be liable for interest on any money
received by it except as the Collateral Agent may agree in writing with the Grantors. Money held in trust by the Collateral Agent need not be segregated from other funds except to the extent required by law. 

8.3 Rights of the Collateral Agent. 

(a) The Collateral Agent may conclusively rely and shall be fully protected in acting or refraining from acting on any
document believed by it to be genuine and to have been signed or presented by the proper Person. The Collateral Agent need not investigate any fact or matter stated in any such document. The Collateral Agent shall not be obligated to communicate
with or deal in any way with any Secured Party other than the Trustee. 
 (b) The Collateral Agent may act
through its attorneys and agents and shall not be responsible for the misconduct or negligence of any attorney or agent appointed with due care. 
 (c) The Collateral Agent shall not be liable for any action it takes or omits to take in good faith that it believes to be authorized or within the rights or powers conferred upon it by this Agreement or
any other Collateral Document. Whenever in the administration of the Indenture, this Agreement or any Collateral Document the Collateral Agent shall deem it desirable that a matter be proved or established prior to taking, suffering or omitting any
action hereunder, the Collateral Agent (unless other evidence be herein specifically prescribed) may, in the absence of bad faith on its part, conclusively rely upon an Officers’ Certificate or an Opinion of Counsel, as applicable, at the
expense of the Company. In no event shall the Collateral Agent be liable under or in connection with the Indenture, this Agreement or other Collateral Documents for indirect, special, incidental, punitive or consequential losses or damages of any
kind whatsoever, including but not limited to lost profits, whether or not foreseeable, even if the Collateral Agent has been advised of the possibility thereof and regardless of the form of action in which such damages are sought. 

(d) Unless otherwise specifically provided in the Indenture, this Agreement or any other Collateral Document, any demand,
request, direction or notice from any Grantor shall be sufficient if evidenced by an Officer’s Certificate. 

(e) The Collateral Agent shall be under no obligation to exercise any of the rights or powers vested in it by the
Indenture, this Agreement or any other Collateral Document at the request or direction of any of the Secured Parties unless such Secured Parties shall have offered to the Collateral Agent security and indemnity satisfactory to the Collateral Agent
against the costs, expenses and liabilities that might be incurred by it in compliance with such request or direction. 
 (f) The Collateral Agent shall not be bound to make any investigation into the facts or matters stated in any resolution, certificate, statement, instrument, opinion, report, notice, request, direction,
consent, order, bond, debenture, note, other evidence of indebtedness or other paper or documents, but the Collateral Agent, in its discretion, may make such further 

  
 12 

 
inquiry or investigation into such facts or matters as it may see fit, and, if the Collateral Agent shall determine to make such further inquiry or investigation, it shall be entitled to examine
during normal business hours and upon reasonable notice the books, records and premises of any Grantor, personally or by agent or attorney at the sole cost of the Grantors, and shall incur no liability or additional liability of any kind by reason
of such inquiry or investigation. 
 (g) The rights, privileges, protections and benefits given to the Collateral
Agent, including, without limitation, its rights to be indemnified, are extended to, and shall be enforceable by, the Collateral Agent in each of its capacities hereunder, and to each agent, custodian and other Persons employed to act hereunder or
under any Collateral Document. 
 (h) The Collateral Agent may request that the Grantors deliver an
Officers’ Certificate setting forth the names of individuals and/or titles of officers authorized at such time to take specified actions pursuant to the Indenture, this Agreement or any other Collateral Document, which Officers’
Certificate may be signed by any person authorized to sign an Officers’ Certificate, including any person specified as so authorized in any such certificate previously delivered and not superseded. 

(i) In connection with exercising any right or discretionary duty hereunder or under any of the Collateral Documents, the
Collateral Agent shall be entitled to rely upon the direction of the Holders of a majority in aggregate principal amount of the Securities. The Collateral Agent shall not have any liability for taking any action at the direction of such party, or
for any failure or delay of any such party to provide timely direction to the Collateral Agent. Notwithstanding any other provision of this Agreement, (i) any such direction may not conflict with any rule of law or with this Agreement and
(ii) the Collateral Agent shall not be required to take any action that it determines might involve it in liability (unless the Collateral Agent has received satisfactory indemnity or security against such liability). 

(j) The Collateral Agent shall enjoy all the same rights, protections, immunities and indemnities granted to it and to the
Trustee under the Indenture as though set forth in full herein (with any references to the Trustee therein being deemed to refer to the Collateral Agent). All of such rights, protections, immunities and indemnities shall survive resignation or
removal of the Collateral Agent and termination of this Agreement. In performing its functions and duties solely under this Agreement, the Collateral Agent shall act solely as the agent of the Secured Parties and does not assume, nor shall be deemed
to have assumed, any obligation or relationship of trust with or for the Secured Parties. The Collateral Agent will be compensated pursuant to a fee agreement with the Company. 

(k) The Collateral Agent may consult with legal counsel, independent public accountants and other experts selected by it
at the expense of the Company and shall not be liable for any action taken or omitted to be taken by it in good faith in accordance with the advice of such counsel, accountants or experts. 

8.4 Individual Rights of Collateral Agent. 

Notwithstanding anything to the contrary, the Collateral Agent in its individual or any other capacity may become the
owner or pledgee of Secured Obligations and may otherwise deal with any Grantor or any Affiliate of any Grantor with the same rights it would have if it were not the Collateral Agent. 

8.5 Collateral Agent’s Disclaimer. 

The Collateral Agent shall not be responsible for and makes no representation as to the validity or adequacy of this
Agreement or any other Collateral Document, or the existence, genuineness, value or protection of any Collateral (except for the safe custody of Collateral in its possession and the accounting for proceeds of Collateral actually received by it in
accordance with the terms hereof), the legality, effectiveness or sufficiency of any Collateral Document, or the creation, perfection, priority, sufficiency or protection of any Lien on any Collateral, and it shall not be responsible for any
statement or recital in this Agreement or any other Collateral Document. 
 8.6 Replacement of Collateral
Agent. 
 (a) A resignation or removal of the Collateral Agent and appointment of a successor
Collateral Agent shall become effective only upon the successor Collateral Agent’s acceptance of appointment as provided in this Section 8.6. The Collateral Agent may resign in writing at any time by so notifying the Company and the
Trustee. The Company may remove the Collateral Agent if: 
 (i) the Collateral Agent is removed as Trustee under
the Indenture; 
 (ii) the Collateral Agent fails to comply with Section 8.2 hereof; 

  
 13 

 (iii) the Collateral Agent is adjudged a bankrupt or an insolvent or an
order for relief is entered with respect to the Collateral Agent under the Bankruptcy Code; 
 (iv) a custodian
or public officer takes charge of the Collateral Agent or its property; or 
 (v) in the reasonable discretion
of the Company, the Collateral Agent becomes incapable of acting. 
 (b) If the Collateral Agent resigns or is
removed or if a vacancy exists in the office of the Collateral Agent for any reason, the Company shall promptly appoint a successor Collateral Agent which complies with any eligibility requirements contained in the Indenture. 

(c) If a successor Collateral Agent does not take office within 30 days after the retiring Collateral Agent
resigns or is removed, the retiring Collateral Agent, the Company or the holders of at least 10% in principal amount of the then outstanding principal amount of Secured Obligations may petition any court of competent jurisdiction for the
appointment of a successor Collateral Agent. 
 (d) A successor Collateral Agent shall deliver a written
acceptance of its appointment to the retiring Collateral Agent and to the Company. Thereupon, the resignation or removal of the retiring Collateral Agent shall become effective, and the successor Collateral Agent shall have all the rights, powers
and the duties of the Collateral Agent under this Agreement and the other Collateral Documents. The successor Collateral Agent shall mail a notice of its succession to the Trustee. The retiring Collateral Agent shall promptly transfer all property
held by it as Collateral Agent to the successor Collateral Agent, subject to its right to receive payments due and owing to it. 
 (e) If U.S. Bank National Association is removed or resigns as Trustee and as Collateral Agent, such resignation or removal shall only become effective upon both a successor Trustee and Collateral Agent
being appointed hereunder and under the Indenture. 
 8.7 Successor Collateral Agent by Merger, Etc.

 If the Collateral Agent consolidates, merges or converts into, or transfers or sells all or substantially
all of its corporate trust business to, another Person, the successor Person without any further act shall be the successor Collateral Agent under this Agreement and the other Collateral Documents. 

8.8 Eligibility. 
 There shall at all times be a Collateral Agent hereunder that meets the requirements for being a trustee under the Indenture (prior to the discharge or defeasance of the Indenture). 

8.9 Co-Collateral Agent; Separate Collateral Agent. 

At any time or times, for the purpose of meeting the legal requirements of any jurisdiction in which any of the Collateral
may at the time be located, the Company and the Collateral Agent shall have the power to appoint agents and sub-agents to the extent permitted under the Indenture. 

8.10 Liability; Enforcement Expenses; Indemnification 

(a) Neither the Collateral Agent nor any of its affiliates, directors, officers, agents or employees shall be liable for
any action taken or not taken by it in connection herewith (i) with the consent or at the request or direction of a Secured Party as provided herein or (ii) in the absence of its own gross negligence or willful misconduct. Neither the
Collateral Agent nor any of its affiliates, directors, officers, agents or employees shall be responsible for or have any duty to ascertain, inquire into or verify (i) any statement, warranty or representation made in connection with this
Agreement; (ii) the performance or observance of any of the covenants or agreements of the Grantors; (iii) the receipt of items required to be delivered to the Collateral Agent; or (iv) the validity, effectiveness or genuineness of
this Agreement, the other Collateral Documents or any other instrument or writing furnished in connection herewith. The Collateral Agent shall not incur any liability by acting in reliance upon any notice, consent, certificate, statement, or other
writing (which may be a bank wire, telex or similar writing) reasonably believed by it to be genuine or to be signed by the proper party or parties. The Collateral Agent shall in all cases be fully protected in acting, or in refraining from acting,
under this Agreement or any other Collateral Document or any other document furnished in connection herewith or therewith in accordance with a written direction or a request of the Grantors or Secured Parties pursuant to the terms of this Agreement
or other Collateral Document. 

  
 14 

 (b) Each Grantor jointly and severally agrees to pay, indemnify and hold
harmless or reimburse the Collateral Agent for all its reasonable, out-of-pocket costs and expenses incurred in collecting against such Grantor and enforcing or preserving any rights under this Agreement and the other Collateral Documents,
including, without limitation, the reasonable, out-of-pocket fees and disbursements of counsel to the Collateral Agent. 
 (c) Each Grantor agrees to pay, indemnify and to hold the Collateral Agent harmless from, any and all liabilities with respect to, or resulting from any delay in paying, any and all stamp, excise, sales
or other taxes (if any) which may be payable or determined to be payable with respect to any of the Collateral or in connection with any of the transactions contemplated by this Agreement. 

(d) Each Grantor agrees to pay, indemnify and to hold the Collateral Agent harmless from any and all liabilities,
obligations, losses, damages, penalties, actions, judgments, suits, costs, expenses or disbursements of any kind or nature whatsoever incurred without gross negligence or willful misconduct with respect to the execution, delivery, enforcement,
performance and administration of this Agreement and any agreement entered into in connection with or in furtherance of this Agreement or its role as Collateral Agent. 

(e) The agreements in this Section shall survive (i) any resignation or removal of the Collateral Agent hereunder or
(ii) repayment of the Obligations and all other amounts payable under the Indenture, the Collateral Documents and the Securities. 

SECTION 9. REMEDIES. 
 9.1 Generally. Subject to the provisions of the Indenture: 

(a) If any Event of Default shall have occurred and be continuing, the Collateral Agent may exercise in respect of the
Collateral, in addition to all other rights and remedies provided for herein or otherwise available to it at law or in equity, all the rights and remedies of the Collateral Agent on default under the UCC (whether or not the UCC applies to the
affected Collateral) to collect, enforce or satisfy any Secured Obligations then owing, whether by acceleration or otherwise, and also may pursue any of the following separately, successively or simultaneously: 

(i) require any Grantor to, and each Grantor hereby agrees that it shall at its expense and promptly upon request of the
Collateral Agent forthwith, assemble all or part of the Collateral as directed by the Collateral Agent and make it available to the Collateral Agent at a place to be designated by the Collateral Agent that is reasonably convenient to both parties;

 (ii) enter onto the property where any Collateral is located and take possession thereof with or without
judicial process; 
 (iii) prior to the disposition of the Collateral, store, process, repair or recondition the
Collateral or otherwise prepare the Collateral for disposition in any manner to the extent the Collateral Agent deems appropriate; 
 (iv) without notice except as specified below or under the UCC, sell, assign, lease, license (on an exclusive or nonexclusive basis) or otherwise dispose of the Collateral or any part thereof in one or
more parcels at public or private sale, at any of the Collateral Agent’s offices or elsewhere, for cash, on credit or for future delivery, at such time or times and at such price or prices and upon such other terms as the Collateral Agent may
deem commercially reasonable; and 
 (v) exercise voting and other consensual rights with respect to the
Investment Related Property. 
 (b) The Collateral Agent or any other Secured Party may be the purchaser of any
or all of the Collateral at any public or private (to the extent the portion of the Collateral being privately sold is of a kind that is customarily sold on a recognized market or the subject of widely distributed standard price quotations) sale in
accordance with the UCC and the Collateral Agent or any other Secured Party, shall be entitled, for the purpose of bidding and making settlement or payment of the purchase price for all or any portion of the Collateral sold at any such sale made in
accordance with the UCC, to use and apply any of the Secured Obligations as a credit on account of the purchase price for any Collateral payable by the Collateral Agent or any other Secured Party at such sale. Each purchaser at any such sale shall
hold the property sold absolutely free from any claim or right on the part of any Grantor, and each Grantor hereby waives (to the extent permitted by applicable law) all rights of redemption, stay and/or appraisal which it now has or may at any time
in the future have under any rule of law or statute now existing or hereafter enacted. Each Grantor agrees that, to the extent notice of sale shall be required by law, at least ten (10) days notice (or such lesser time as commercially
reasonable) to such Grantor of the time and place of any public sale or the time after which any private sale is to be made shall constitute reasonable 

  
 15 

 
notification. The Collateral Agent shall not be obligated to make any sale of Collateral regardless of notice of sale having been given. The Collateral Agent may adjourn any public or private
sale from time to time by announcement at the time and place fixed therefor, and such sale may, without further notice, be made at the time and place to which it was so adjourned. Each Grantor agrees that it would not be commercially unreasonable
for the Collateral Agent to dispose of the Collateral or any portion thereof by using Internet sites that provide for the auction of assets of the types included in the Collateral or that have the reasonable capability of doing so, or that match
buyers and sellers of assets. Each Grantor hereby waives any claims against the Collateral Agent arising by reason of the fact that the price at which any Collateral may have been sold at such a private sale was less than the price which might have
been obtained at a public sale, even if the Collateral Agent accepts the first offer received and does not offer such Collateral to more than one offeree. If the proceeds of any sale or other disposition of the Collateral are insufficient to pay all
the Secured Obligations, Grantors shall be liable for the deficiency and the reasonable fees the Collateral Agent and of any attorneys employed by the Collateral Agent to collect such deficiency. Each Grantor further agrees that a breach of any of
the covenants contained in this Section will cause irreparable injury to the Collateral Agent, that the Collateral Agent has no adequate remedy at law in respect of such breach and, as a consequence, that each and every covenant contained in this
Section shall be specifically enforceable against such Grantor, and such Grantor hereby waives and agrees not to assert any defenses against an action for specific performance of such covenants except for a defense that no default has occurred
giving rise to the Secured Obligations becoming due and payable prior to their stated maturities. Nothing in this Section shall in any way limit the rights of the Collateral Agent hereunder. 

(c) The Collateral Agent may sell the Collateral without giving any warranties as to the Collateral. The Collateral Agent
may specifically disclaim or modify any representations and warranties of title or the like. This procedure will not be considered to adversely affect the commercial reasonableness of any sale of the Collateral. 

(d) The Collateral Agent shall have no obligation to marshal any of the Collateral. 

9.2 Application of Proceeds. All proceeds received by the Collateral Agent in respect of any sale of, any
collection from, or other realization upon all or any part of the Collateral (less all the costs and expenses of the Collateral Agent in respect of such sale or collection) shall be applied in accordance with Section 6.10 of the
Indenture. 
 9.3 [Reserved]. 

9.4 Investment Related Property. Subject to the provisions of this Agreement and the Indenture, each Grantor
recognizes that, by reason of certain prohibitions contained in the Securities Act and applicable state securities laws, the Collateral Agent may be compelled, with respect to any sale of all or any part of the Investment Related Property conducted
without prior registration or qualification of such Investment Related Property under the Securities Act and/or such state securities laws, to limit purchasers to those who will agree, among other things, to acquire the Investment Related Property
for their own account, for investment and not with a view to the distribution or resale thereof (such sale, a “private sale” for purposes of this Section). Each Grantor acknowledges that such private sale may be viewed as a “public
sale” for purposes of the UCC. Each Grantor acknowledges that any such private sale may be at prices and on terms less favorable than those obtainable through a “public sale” for purposes of the Securities Act without such
restrictions (including a public offering made pursuant to a registration statement under the Securities Act) and, notwithstanding such circumstances, each Grantor agrees that any such private sale shall be deemed to have been made in a commercially
reasonable manner and that the Collateral Agent shall have no obligation to engage in public sales and no obligation to delay the sale of any Investment Related Property for the period of time necessary to permit the issuer thereof to register it
for a form of public sale requiring registration under the Securities Act or under applicable state securities laws, even if such issuer would, or should, agree to so register it. If the Collateral Agent determines to exercise its right to sell any
or all of the Investment Related Property, upon written request, each Grantor shall and shall cause each issuer of any Pledged Stock to be sold hereunder, each partnership and each limited liability company from time to time to furnish to the
Collateral Agent all such information as the Collateral Agent may request in order to determine the number and nature of interest, shares or other instruments included in the Investment Related Property which may be sold by the Collateral Agent in
exempt transactions under the Securities Act and the rules and regulations of the Securities and Exchange Commission thereunder, as the same are from time to time in effect. 

  
 16 

 9.5 Intellectual Property License 

Subject to the provisions of this Agreement and the Indenture, the Company (individually and on behalf of each of the
Grantors) hereby grants to the Collateral Agent a limited non-exclusive, irrevocable, perpetual (until terminated in accordance with this Agreement), world-wide, royalty-free license (which shall include without limitation the right to grant
sublicenses) to use and exploit the Grantor’s Intellectual Property in any manner whatsoever, including without limitation the right to make, use, sell, offer for sale, import and export products and services incorporating such Intellectual
Property for the sole purpose of enabling the Collateral Agent, during the continuance of an Event of Default, to exercise rights and remedies under Section 9 hereof at such time, as the Collateral Agent shall be lawfully entitled to exercise
such rights and remedies. The license granted hereunder shall be subject to all licenses granted by the Grantors to other persons, and, with respect to Trademarks, in the event the license set forth in this Section is exercised with regard to any
Trademarks, then the licensed Trademarks shall only be used in association with goods or services of a quality and nature consistent with the quality and reputation with which such Trademarks were associated when used by Grantors prior to the
exercise of the license rights set forth herein. 
 SECTION 10. COLLATERAL AGENT. 

The Collateral Agent has been appointed to act as Collateral Agent hereunder by the Securityholders. The Collateral Agent shall have the
right hereunder, to make demands, to give notices, to exercise or refrain from exercising any rights, and to take or refrain from taking any action (including, without limitation, the release or substitution of Collateral), solely in accordance with
this Agreement and the Indenture. In furtherance of the foregoing provisions of this Section 10, each Securityholder, by its acceptance of the benefits hereof, agrees that it shall have no right individually to realize upon any of the
Collateral hereunder, it being understood and agreed by such Secured Party that all rights and remedies hereunder may be exercised solely by the Collateral Agent for the benefit of Secured Parties in accordance with the terms of this Section. The
provisions of the Indenture relating to the Collateral Agent including, without limitation, the provisions relating to resignation or removal of the Collateral Agent and the powers and duties and immunities of the Collateral Agent are incorporated
herein by this reference and shall survive any termination of the Indenture and resignation or removal of the Collateral Agent. 
 SECTION
11. CONTINUING SECURITY INTEREST; TRANSFER OF NOTES. 
 This Agreement shall create a continuing security interest in the
Collateral and shall remain in full force and effect until the payment in full of all Secured Obligations (other than contingent obligations not yet due and payable), be binding upon each Grantor, its successors and assigns, and inure, together with
the rights and remedies of the Collateral Agent hereunder, to the benefit of the Collateral Agent and its successors, transferees and assigns. Without limiting the generality of the foregoing, but subject to the terms of the Indenture, any
Securityholder may assign or otherwise transfer any Notes held by it to any other Person, and such other Person shall thereupon become vested with all the benefits in respect thereof granted to Securityholders herein or otherwise. Upon the payment
in full of all Secured Obligations (other than contingent obligations not yet due and payable), the security interest granted hereby shall automatically terminate hereunder and of record and all rights to the Collateral shall revert to the Grantors.
Upon any such termination the Collateral Agent shall, at the Grantors’ expense, execute and deliver to the Grantors or otherwise authorize the filing of such documents as the Grantors shall reasonably request, including financing statement
amendments to evidence such termination. Upon any disposition of property permitted by the Indenture, the Liens granted herein and/or under the other Collateral Documents shall be deemed to be automatically released and such property shall
automatically revert to the applicable Grantor with no further action on the part of any Person. The Collateral Agent shall, at the applicable Grantor’s expense, execute and deliver or otherwise authorize the filing of such documents as such
Grantor shall reasonably request, in form and substance reasonably satisfactory to the Collateral Agent, including financing statement amendments to evidence such release. 
 SECTION 12. MISCELLANEOUS. 
 Any notice required or permitted to be given
under this Agreement shall be given in accordance with Section 12.02 of the Indenture. No failure or delay on the part of the Collateral Agent in the exercise of any power, right or privilege hereunder or under the Indenture shall impair such
power, right or privilege or be construed to be a waiver of any default or acquiescence therein, nor shall any single or partial exercise of any such power, right or privilege preclude other or further exercise thereof or of any other power, right
or privilege. All rights and remedies existing under this Agreement and the other Collateral Documents are cumulative to, and not exclusive of, any rights or remedies otherwise available. In case any provision in or obligation under this Agreement
shall be invalid, illegal or unenforceable in any jurisdiction, the validity, legality and enforceability of the remaining provisions or Obligations, or of such provision or obligation in any other jurisdiction, shall not in any way be affected or
impaired thereby. All covenants hereunder shall be given independent effect so that if a particular action or condition is not permitted by any of such covenants, the fact that it would be permitted by an exception to, or would otherwise be within
the limitations of, another covenant shall not avoid the occurrence of a Default or an Event of Default if such action is taken or condition exists. This Agreement shall be binding upon and inure to the benefit of the Collateral Agent and the
Grantors and 

  
 17 

 
their respective successors and permitted assigns. No Grantor shall assign any right, duty or obligation hereunder except as permitted by the Indenture. This Agreement, the Indenture, the
Securities and the other Collateral Documents embody the entire agreement and understanding between the Grantors and the Collateral Agent and supersede all prior agreements and understandings between such parties relating to the subject matter
hereof and thereof. Accordingly, the Collateral Documents may not be contradicted by evidence of prior, contemporaneous or subsequent oral agreements of the parties. There are no unwritten oral agreements between the parties. This Agreement may be
executed in one or more counterparts (including by telecopy or other electronic transmission, including by .pdf or similar file) and by different parties hereto in separate counterparts, each of which when so executed and delivered shall be deemed
an original, but all such counterparts together shall constitute but one and the same instrument; signature pages may be detached from multiple separate counterparts and attached to a single counterpart so that all signature pages are physically
attached to the same document. 
 SECTION 13. CONFLICTS. 
 In the event of any conflict or inconsistency between the provisions of this Agreement and the Indenture, the provisions of the Indenture shall govern. 

[Remainder of page intentionally left blank] 

  
 18 

 IN WITNESS WHEREOF, each Grantor and the Collateral Agent have caused this Agreement to be
duly executed and delivered by their respective officers thereunto duly authorized as of the date first written above. 
  

					
	Savient Pharmaceuticals, Inc., as a Grantor
		
	By:	 	/s/ Philip K. Yachmetz
		 	Name:	 	Philip K. Yachmetz
		 	Title:	 	Senior Vice President, General Counsel & Secretary

  

					
	Savient Pharma Holdings, Inc., as a Grantor
		
	By:	 	/s/ Philip K. Yachmetz
		 	Name:	 	Philip K. Yachmetz
		 	Title:	 	Senior Vice President & General Counsel

  

					
	Savient Pharma Ireland Limited, as a Grantor
		
	By:	 	/s/ Philip K. Yachmetz
		 	Name:	 	Philip K. Yachmetz
		 	Title:	 	Senior Vice President, Legal & Compliance & Company Secretary, and Director

 [Signature Page to Pledge and Security Agreement] 

 
					
	U.S. BANK NATIONAL ASSOCIATION, as Collateral Agent
		
	By:	 	/s/ Rick Barnes
		 	Name:	 	Rick Barnes
		 	Title:	 	Vice President

 [Signature Page to Pledge and Security Agreement] 

 SCHEDULE 5.4 
 Filings/Filing Offices 

 EXHIBIT A 
 PLEDGE SUPPLEMENT 

 EXHIBIT B 
  

[Form of] 

UNCERTIFICATED SECURITIES CONTROL AGREEMENT 

 EXHIBIT C 
 [Form of] 
 IP SECURITY AGREEMENT 

INTELLECTUAL PROPERTY SECURITY AGREEMENT dated as of May 9, 2012, by SAVIENT PHARMACEUTICALS, INC., a Delaware Corporation (the
“Grantor”), in favor of U.S. BANK NATIONAL ASSOCIATION (the “Collateral Agent”). 
 WHEREAS,
pursuant to that certain Pledge and Security Agreement, of even date herewith (as amended, restated, supplemented or otherwise modified from time to time, the “Security Agreement”), among the Grantor, the Collateral Agent and
certain other parties thereto, in order to secure payments of certain Secured Obligations (as defined in the Security Agreement), the Grantor hereby assigns, pledges and grants to the Collateral Agent a continuing security interest in and to all of
the Collateral whether now owned or hereinafter acquired and whether now existing or hereafter arising (as defined in the Security Agreement) including, without limitation, the copyrights listed on Schedule I hereto, and the trademarks and
trademark applications listed on Schedule II hereto, and the patents listed on Schedule III hereto (the “Intellectual Property”). Until all of the Secured Obligations have been indefeasibly paid in full, the Collateral
Agent shall retain its security interest in the Intellectual Property granted herein and in the Security Agreement. 
 NOW,
THEREFORE, for the consideration set forth herein and in the Security Agreement, the parties hereby agree that the Grantor, as collateral security for the full, prompt and complete payment and performance when due (whether at stated maturity, by
acceleration or otherwise) of its Secured Obligations under the Security Agreement, hereby grants the Collateral Agent a lien on and security interest in, all of its right, title and interest in, to and under the Intellectual Property (including
(i) all reissues, continuations, renewals or extensions of the foregoing, (ii) all goodwill of the business connected with the use of, and symbolized by, each Intellectual Property, and (iii) all products and proceeds of the
foregoing). 
 FOR THE AVOIDANCE OF DOUBT, notwithstanding any other provision of this agreement, the Grantor does not grant any
lien on or security interest in any of the Excluded Assets (as defined in the Security Agreement). 
 [Signature Pages Follow]

 IN WITNESS WHEREOF, Grantor has caused this INTELLECTUAL PROPERTY SECURITY AGREEMENT to be
executed and delivered by its duly authorized officer as of the date first set forth above. 
  

			
	[GRANTOR]
		
	By:	 	 
	Name:	 	
	Title:	 	

					
	ACCEPTED AND ACKNOWLEDGED BY:
	
	U.S. BANK NATIONAL ASSOCIATION
		
	By:	 	 
		 	Name:	 	
		 	Title:	 	

 EXHIBIT D 
 [Form of] 
 PERFECTION CERTIFICATE

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00204-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00204-of-00352.parquet"}]]